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EXECUTIVE SUMMARY  
 
This literature review report is part of the early HTA (Health Technology Assessment) study of NIPD 
(Non-invasive prenatal diagnostics) RhD technology which, as of 2005, is beginning to diffuse into 
practice in a number of European countries and the United States.  The report is written based on the 
application of the initial SAFE HTA framework (see www.safenoe.org), developed through a world-wide 
Delphi process. 
 
 
The Report 
 
This report concentrates on three main areas.   
 
First and foremost, we set the background context for RhD NIPD in prenatal care.  While the 
methodology chapter describes how the literature review was carried out and how additional information 
was collected, the second chapter provides an overview of the key issues associated with pregnancy of 
RhD negative women.  We present background information based on publications from 1997 to 2006 
which describe the genetic condition and its prevalence (RhD negativity) in populations, as well as the 
frequency of cases of sensitisation and HDN (haemolytic disease of the newborn).  We also discuss 
current service provision for RhD negative women in a number of European countries and look at how 
the NIPD test might be set within current service contexts. 
 
For general issues relating to the clinical effectiveness and cost-effectiveness of routine antenatal anti-D 
prophylaxis (RAADP) for pregnant women who are rhesus-negative the reader is referred to an existing 
review published in 2003 as an HTA report and used to develop NICE guidelines in the UK [1].  This 
presents a clear description of the use of anti-D prophylaxis (both postnatal and antenatal) in the 
management of RhD negative pregnancies and prevention of haemolytic disease of the newborn.  
Figures on prevalence of HDN, incidence of sensitisation etc, are available in this report for the UK.  
There is no similar published literature for other countries, and this is therefore the reason for an 
inevitable focus on the UK in some parts of this report, although this data is being sought by the SAFE 
socio-economic team. 
 
Finally, the background section includes evidence on technologies under development that may be 
relevant to decisions on the introduction of NIPD RhD testing, either for sensitised women or in the 
context of RAADP.  Recombinant Anti-D prophylaxis, peptide immunotherapy and preimplantation 
genetic diagnosis are discussed.  
 
Secondly, this report concentrates on the available evidence on the technical performance and 
clinical validity of NIPD RhD tests.  The third chapter provides a description of the studies to date 
which have evaluated the technical performance of RhD NIPD tests, e.g. techniques and material used, 
testing conditions examined, genotype sensitivity/specificity, reference samples and time of testing.  
Weaknesses in study design are pointed out which may influence the validity of test performance 
results.  We also highlight various discoveries in the field of non-invasive prenatal diagnostics, mainly in 
connection with the molecular bases of the RhD gene and its variants, and we report on the first moves 
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towards test standardisation and external quality control (developed by SAFE partners).  In the fourth 
chapter, we discuss the available information on clinical validity of the NIPD RhD technology and look at 
evidence from published scientific papers on how the new test might perform once implemented, paying 
particular attention to the application in multi-ethnic populations. 
 
Finally, the last three chapters look at the broader picture and discuss the limited literature available on 
other issues associated with the implementation of the RhD NIPD technology.  Chapter six describes the 
necessary arrangements for the implementation of the test, assesses evidence on risks and limitations, 
and reports on possible unintended consequences.  Chapter seven briefly describes ongoing 
(unpublished) research in the field, and in chapter eight we highlight gaps in the published literature and 
current knowledge.  The aim of the last two chapters is to set the direction for future research, as well as 
focus the attention of policymakers, healthcare providers and the public on the issues that should be 
considered when make a decision about NIPD RhD introduction. 
 
Main Findings:
 
Size of the problem 
Even though postnatal (postpartum) anti-D prophylaxis has considerably reduced sensitisation, HDN 
due to RhD incompatibility can still result in prenatal/neonatal death.  About 10% of all pregnancies in 
Europe involve an RhD negative mother and an RhD positive fetus, and at least 30 deaths are 
associated with HDN every year in England and Wales alone (c.f. 4,482 perinatal deaths in total in 
2001).  However, this number does not include babies affected by other symptoms of HDN such as 
anaemia, hydrops fetalis, hyperbilirubinemia and jaundice, seizures, brain damage and deafness.  
Furthermore, routine prenatal anti-D prophylaxis is not uncontroversial and a reduction in its application 
could help address issues associated with perceived problems with safety and access to future supplies 
for this blood product. 
 
Role of NIPD tests in patient management 
RhD NIPD can assist in the management of already sensitised women.  It also has the potential to 
reduce the application of unnecessary RAADP to RhD negative women whose pregnancy is not at risk 
(i.e. with RhD negative fetuses) and would, therefore, lead to an improvement in the current 
management of these pregnancies.  It might also help to increase the use of antenatal prophylaxis in 
systems where RAADP is only sporadically administered by health care providers or not practised at all.  
 
Implementation of routine NIPD RhD testing for RAADP 
At present, successful universal introduction of this new technology is most likely to be hampered by the 
following issues: 
 
First, no standardised methodology for NIPD RHD genotyping is currently available, although this is 
being addressed by the SAFE standardisation activity. 
 
Second, current tests may not be sufficiently reliable for individuals with RHD gene variants, although, 
markers are being developed and tested by the SAFE Network of Excellence (NoE) partners. 
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Third, there is limited evidence to demonstrate cost-effectiveness of pan-European technology 
introduction.  The laboratory cost per test in different European countries is estimated to be between 15 
and 27 Euros and the working capital per laboratory is estimated to be ~300,000 Euros for year 1.  Also, 
at present, in terms of organisation there is no indication as to how adapting infrastructure, fully 
automating procedures, creating universal kits for RhD NIPD, and setting up a centralised laboratory 
service might influence cost per test in different countries. 
 
Variations in guidelines for prenatal care in member states and alternative health systems might also 
have an impact on successful implementation.  Currently, in European states which have introduced 
RAADP no policies exist for routine NIPD RhD testing of non-sensitised women.  It appears that 
universal antenatal prophylaxis will not be replaced by NIPD targeted prophylaxis until there is 
quantifiable evidence demonstrating the costs of introduction and socio-economic and other benefits of 
this new technology in different country contexts. 
 
RhD NIPD test performance  
Through searching the major electronic databases, as well as international literature collections, 21 
peer-reviewed papers were identified that in some way evaluate the scientific validity and diagnostic 
sensitivity and specificity of RhD NIPD tests. 
 
The international STARD checklist (Standards for reporting studies of diagnostic accuracy) was applied 
to these published articles to assess the quality of studies.  It was noted that papers failed to comment 
on many points of the checklist.  It was concluded that the identified studies are largely scientific and 
because of various shortcomings they should not be used solely to assess the diagnostic accuracy of 
the new tests.  
 
The list of shortcomings includes: small patient sample numbers in most studies; selective sampling of 
study populations; exclusion of inconclusive results from the overall calculation of accuracy; lack of 
consistency in the definitions of sensitivity and specificity; general reporting of ‘accuracy’ and detection 
rate; lack of reported measures of statistical certainty/uncertainty; and inconsistent consideration of 
replicate outcomes in the overall result.  This list must raise concerns because the issues mentioned 
may have a significant effect on the accuracy of tests in the service setting and, as such, the results 
reported in these studies must be treated with caution. 
 
However, the number of available studies and the countries of origin reflect the global interest in this 
new technology; and the accuracy results reported in studies illustrate the great potential of NIPD 
testing.  The published studies also demonstrate the rapid developments and technical improvements in 
the field of NIPD, and more recent reports about clinical experiences indicate that the technology is in 
the process of being used in an ad hoc manner in several health care systems. 
 
In acknowledgement of the fast development of NIPD RHD genotyping, we also included information 
sources such as grey literature (e.g. unpublished reports) and a number of international interviews 
conducted with bio-scientists and policymakers.  The up-to date evidence contrasts with the conclusions 
drawn from peer-reviewed published studies and demonstrates that NIPD RhD genotyping is currently 
advancing in a number of countries in Europe. 
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Future Outlook  
 
The aim of this report is to provide initial relevant evidence for the initiation of economic modelling of 
NIPD RhD technology.  This will enable us to address questions about the suitability of NIPD tests for 
implementation i.e. establish what are the optimal conditions within health care systems and clinical 
practice for the uptake of non-invasive prenatal RhD diagnostics, and evaluate the risks and benefits as 
well as associated costs, enabling policy makers to forecast the diffusion process into clinical practice 
across European countries.  The ongoing work of the SAFE socio-economic team aims to build on the 
information in this report in order to produce an early-HTA (e-HTA) report highlighting the economic 
benefits or disadvantages of this new technology in different settings 
 
Finally, this report is produced to encourage further research, both scientific, in order to perfect the 
markers for various ethnic groups, and clinical to initiate more population based clinical trials to assess 
the effectiveness of the technology, as well as socio-economic to address cost-effectiveness in different 
in health care systems.  
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LIST OF ABBREVIATIONS  
 
 
AADP Prenatal anti-D prophylaxis 
ABO ABO blood group system 
BPL British Products Laboratory 
CVS Chorionic Villus Sampling 
DNA Deoxyribonucleic acid 
EQA External Quality Assurance  
HDN Haemolytic Disease of the Newborn 
HTA Health Technology Assessment 
IBGRL International Blood Group Reference Laboratory 
IgG Immunoglobulin G 
IgM Immunoglobulin M 
ISBT International Society Blood Transfusion 
MeSH Medical Subject Headings 
mRNA Messenger ribonucleic acid 
NICE National Institute of Clinical Excellence 
NIPD Non-invasive Prenatal Diagnostics 
NRR National Research Register 
PCR Polymerase Chain Reaction 
QALY Quality Adjusted Life Year 
RAADP Routine Antenatal anti-D Prophylaxis 
rAnti-D Recombinant Anti-D 
RBC Red Blood Cell 
RHAG Rhesus blood group-associated glycoprotein 
RHD/RHCE Rhesus D/CE gene 
ROC Receiver Operating Characteristic 
RQ PCR Real-time quantitative PCR 
SAFE Special Advances in Fetal and Neonatal Evaluation 
SRY Sex-determining region Y 
STARD Standards for reporting studies of diagnostic accuracy 
WP Work Package 
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GLOSSARY 
 
 
Antenatal Anti-D Prophylaxis (AADP) 
If an RhD-negative woman has had, or is believed to have had, a potentially sensitising event during 
pregnancy she will be offered anti-D prophylaxis, an injection of anti-D immunoglobulin, at the time of the 
event: this is known as antenatal anti-D prophylaxis or AADP. 
 
Health Technology Assessment (HTA) 
The systematic evaluation of properties, effects, and/or impacts of health care technology. It may 
address the indirect, unintended consequences as well as direct, intended consequences of 
technologies. Its main purpose is to inform technology-related policymaking in health care. HTA is 
conducted by interdisciplinary groups using explicit analytical frameworks drawing from a variety of 
methods. 
 
Non-Invasive Prenatal Diagnostics (NIPD) 
Prenatal diagnosis is the process of detecting and diagnosing fetal abnormalities before birth. Prenatal 
diagnosis can be divided into invasive and non-invasive techniques. Non-invasive procedures do not 
imply any intervention and are harmless to both the fetus and the mother. Non-invasive techniques 
include maternal serum screening (MSS), ultrasound and analysis of fetal material in the maternal 
circulation. In this report the term NIPD is used for non-invasive prenatal genetic diagnostic testing using 
fetal nucleic acids derived from maternal plasma or serum. 
 
Perinatal death 
Deaths occurring during late pregnancy (at 22 completed weeks gestation and over), during childbirth 
and up to seven completed days of life [WHO]. 
 
Positive controls  
A positive control is a control experiment in which the desired outcome confirms the validity of the 
experiment. In the case of RhD NIPD, a positive control confirms the presence of DNA in a sample that 
tests RhD negative.  
 
Positive predictive value (PPV) and Negative predictive value (NPV) 
PPV is the proportion of those individuals with a positive test result who actually have the condition.  
NPV is the proportion of individuals with a negative test result who actually do not have the condition. 
 
Replicates 
A replicate is when two or more experimental units carry the same explanatory values. 
Technical replicates are repeated measures (statistically).  There are four variables that are linked to the 
number of replicates: variability, effect size, false positive rate, and power, i.e. determining the number of 
replicates depends on the significance we are looking for, the relative effect size for each gene, and the 
importance of not missing potential targets. 
The number of replicates should be independent of the gene because different genes may have different 
inherent variability [96].  
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Routine Antenatal Anti-D Prophylaxis (RAADP) 
Routine antenatal anti-D prophylaxis (RAADP), an injection of anti-D immunoglobulin, is given by 
injection to all pregnant women who are RhD-negative usually at weeks 28 and 34 (two dose policy UK) 
or around week 30 (one dose policy other European countries) of their pregnancy.  
 
Sensitivity and Specificity 
Sensitivity is defined as the ability of a test to detect a disease or condition when this is present, thus 
sensitivity is the proportion of diseased patients with a positive test. 
 
Specificity is the ability of a test to correctly exclude the disease or condition in non-diseased 
populations, thus specificity is the proportion of non-diseased patients with a negative test. 
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1 METHODOLOGY 
 
1.1 Literature Review  
 
1.1.1  Literature search strategy 
 
Published and grey literature reporting findings on the scientific validity and diagnostic accuracy of RhD 
NIPD was identified; systematic searches of electronic databases for papers and conference abstracts; 
browsing international literature collections; and examining bibliographies in key papers.  Electronic 
databases searched included Medline, Embase, the Cochrane Library, Index to Theses, the National 
Electronic Library for Health (UK), and Conference Papers. Searches were limited to papers published in 
1998 and thereafter.  This decision is justified by the date of discovery of free fetal DNA in maternal 
circulation by Lo et al. [5] which is the material of choice for non-invasive fetal RHD genotyping.  
Additionally, ongoing studies were sought in the UK National Research Register (NRR).  The literature 
search was updated regularly during the period May 2005 to January 2006.  Experts working in the field 
were also contacted in order to validate the completeness of the evidence sources identified.   
 
1.1.2  Published articles and reports identified 
 
28 published articles were identified.  The majority were in English, one was in Polish, one in Dutch and 
two in French.  Papers were identified in the following journals: 
• American Journal of Obstetrics and Gynecology 
• Annals of the New York Academy of Science 
• British Journal of Haematology 
• British Journal of Obstetrics and Gynaecology 
• European Journal of Obstetrics and Gynecology and Reproductive Biology 
• Journal of Histochemistry and Cytochemistry  
• Molecular Diagnosis 
• New England Journal of Medicine 
• Prenatal Diagnosis,  
• Transfusion 
• Vox Sanguinis 
 
The articles evidence the widespread interest in this new technology with the following 14 countries 
having published a study in this field: Australia; Belgium; Czech Republic; Denmark; France; Germany; 
Ireland; Netherlands; Norway; Poland; Spain; Switzerland; UK; USA. 
 
Searching the NRR resulted in the discovery of two additional registered studies.  One was carried out at 
the University of the West of England in Bristol and included 200 multi-ethnic women.  The lead 
researcher was contacted and a  report from this study obtained. The second study is still ongoing in 
Scotland at the time this report was written (100 primigravidae). 
 
Lastly, a study by the Health Care Efficiency Research Programme in the Netherlands was identified 
[11] and a copy of their final report was provided by the Dutch research group. 
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1.1.3  Inclusion criteria 
 
Full text articles and reports were retrieved and examined.  Papers were examined and 
excluded if they did not report findings on the scientific validity or diagnostic accuracy of RhD 
NIPD.  Seven papers were excluded at this stage: 
• one case reports 
• three reviews 
• two letters 
• one abstract  
 
One grey literature report was included (Netherlands) not only because it reports the largest study 
undertaken to date (2,543 women), but also because of its useful information on the development of the 
NIPD test under study. 
 
Papers and reports excluded from the main review were used for additional, supporting information. 
 
1.1.4  Data extraction strategy 
 
A proforma was constructed for data extraction from the 21 included papers.   Information was extracted 
covering the following topics: 
• study type 
• year and country of publication 
• study aim 
• number of samples tested 
• method and reference test 
• testing strategy (exons and introns tested and whether fetal cells or free fetal DNA was used) 
• number of replicates 
• Reported test accuracy/sensitivity and specificity  
• study outcome  
 
1.1.5  Quality assessment strategy 
 
Assessment of the quality of papers reporting studies of diagnostic accuracy was undertaken using the 
STARD (Standards for reporting studies of diagnostic accuracy) checklist.  This checklist (see Annex 1) 
is the result of an international initiative by scientists and editors to improve the quality of reporting of 
studies of diagnostic accuracy [73].  The checklist is now required as an annex for all health technology 
assessment (HTA) reports on diagnostic technologies in the UK and increasingly requested by editors of 
international journals for papers accepted.  
 
Altogether 21 papers were examined and data extracted (see Annex 2).  A STARD score out of 25 was 
also assigned to every paper by a single reviewer. 
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1.2 Other Information Sources and Delphi Panel 
 
In addition to examination of published articles, stakeholder interviews and surveys were also conducted 
using different media (online questionnaires, Horizon Wimba, teleconferencing) and in person.  These 
were used to explore specific issues associated with the potential introduction of non-invasive fetal RHD 
genotype testing in different countries.   
 
A Delphi Panel of key experts in 24 countries has also been established.  This consists of 90 individuals 
and includes experts from national HTA agencies/ HTA leads, international HTA networks, clinicians/ 
laboratory service providers, patient/ user groups, bio-scientists developing these new tests, industrial 
entrepreneurs/ manufacturers and other individuals with expertise in ethics, law, epidemiology and social 
sciences.   
 
An initial Delphi exercise has been completed to identify a list of key questions to be addressed in  
health technology assessments of emerging prenatal genetic tests [12]. This initial framework has been 
used to help structure the material in this review. 
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2 BACKGROUND  
 
2.1 Description of the Genetic Character and Sensitisation in Pregnancy 
 
The inheritance of a genetic character determined by a single gene, such as Rhesus blood group 
system, follows a distinctive pattern from generation to generation.  In the case of the rhesus system 
gene, there are two variants (alleles) one associated with rhesus positive phenotype (R) and one with 
rhesus negative phenotype (r).  A person with two copies of the r allele (rr) on a pair of chromosomes 
will be rhesus negative, and those with RR will be rhesus positive.  Both are said to be homozygous 
because the two copies of the gene are the same.  In cases where they differ (rR, Rr) they are said to be 
heterozygous.  Because rhesus negative is recessive it is masked by the dominant rhesus positive, and 
heterozygous individuals are rhesus positive.  If the r allele had been dominant, both would be rhesus 
negative. 
 
In more detail, the RHD gene, which encodes for a red blood cell antigen, is one of two highly 
homologous (i.e. 'having a similar structure') genes of the Rh blood group system, the other gene being 
RHCE.  A genetic mechanism termed 'crossing over' can result in the complete deletion of the RHD 
gene [14].  Individuals, who are homozygous for this deletion, are consequently RhD negative.  This is 
the case for most RhD negative white Caucasians.  However, in other population groups, e.g. Africans, 
the situation is more complex (see [13] for more details).  RhD negativity is characterised by the 
absence of the RhD antigen.  Contact of RhD negative blood with RhD antigens, present for example in 
RhD positive blood, will result in an immunogenic response, in other words the production of antibodies 
against the antigen.  This can occur, for instance, if the RhD positive blood of a fetus comes in contact 
with the circulation of an RhD negative mother.  
 
The process of antibody formation against the RhD antigen in the RhD negative mother after feto-
maternal haemorrhage is termed sensitisation and can occur before as well as during the birth of an 
RhD-positive child [29].  This blood incompatibility can lead to RhD haemolytic disease of the 
fetus/newborn (HDN) in an RhD positive fetus.  This is characterised by the destruction of fetal red blood 
cells by maternally produced antibodies.  Symptoms of HDN range from mild anaemia to the death of 
the fetus, and can include jaundice, physical disability, and mental retardation.  Haemolytic disease does 
not (normally) occur in first time pregnancies because large feto-maternal haemorrhages are most likely 
to occur in late pregnancy.  Furthermore, antibody production takes time and the first antibodies 
produced - IgM (immunoglobulin of the primary response) - are not able to cross the placenta.  However, 
if sensitisation does occur during the first pregnancy all subsequent pregnancies with RhD positive 
fetuses are at risk of HDN.  This is due to IgG, the principal antibody of the secondary immune response 
being able to cross the placenta. 
 
2.1.1 Evidence on prevalence of RhD negativity across population groups 
 
About 15% of the white Caucasian population is RhD negative.  In such populations, approximately 10% 
of all pregnancies involve a Rhesus negative mother and a Rhesus positive fetus.  In a first pregnancy, 
60% of Rhesus negative mothers will have a positive child [1, Annex 3].  Due to this occurrence, these 
pregnancies are potentially at risk of sensitisation.  
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As pointed out above, RhD negativity occurs in the Caucasian population mainly from the deletion of the 
RHD gene.  However, it can also be the result of other rare factors such as non-functional genes, such 
as hybrid genes or genes with single nucleotide exchanges, multiple nucleotide exchanges, and 
deletions or insertions.  For example, 0.2-1% of Caucasians have reduced expression of the D-antigen 
(called weak D).  Another group of non-functional genes is the partial D type.  DVI is the most common 
partial D type amongst Caucasians [14].  Non-functional genes may have an impact on the clinical 
validity of non-invasive fetal RHD genotyping due to the resulting disagreement between genotype and 
phenotype (i.e. rhesus positive or rhesus negative). 
 
Although prevalence of the RhD negative phenotype is less frequent in minority ethnic groups (e.g. 8% 
in Black Africans and 2% in the South Asian population), the genotype shows greater variability in these 
groups.  Implementation of testing in an ethnically diverse population will therefore require consideration 
of these variable genotypes.  In Asians and Black Africans RhD negativity is often caused by a silent or 
inactive RHD gene rather than a deleted gene.  While their phenotype is negative, the presence of parts 
of the gene sequence can result in a positive result when genotyped.  For example, 66% of black 
Africans have RHD genes (RHDΨ) that contain a 37-bp insertion which results in a premature stop 
codon and 15% carry a hybrid RHD-CE-D (ceS), characterised by the expression of weak C and no D 
antigen which means that carriers of these hybrid genes are phenotypical RhD negative, while 
genotyping would result in a positive result.  Many D-negative Asians, on the other hand, carry the Del 
gene which shows only a low-level expression of the D antigen while the RHD gene is grossly intact, 
potentially causing the same kind of mistyping as above [14].   
 
The variety of RHD genotypes makes the development of a universal non-invasive prenatal diagnostic 
testing kit, with an application range that includes all ethnic groups, more challenging. 
 
2.1.2  Evidence on incidence of sensitisation in pregnancy 
 
The greatest risks of sensitisation occur at delivery, after abortion and after invasive procedures.  
Without prophylaxis when these events occur: 5-15% of RhD negative pregnant women will develop 
anti-D antibodies at delivery; 3-6% after spontaneous abortion; and 2-5% during amniocentesis [15, 16].  
 
In the absence of a high risk event pre-delivery, and if no prenatal prophylaxis is administered, 1-2% of 
RhD negative pregnant women will become sensitised before birth due to feto-maternal haemorrhage 
[15].  The actual risk attached to sensitisation in an individual pregnancy will depend on various factors.  
For example, ABO mismatch between mother and fetus has a partial protective effect against RhD 
sensitisation [14] which explains, at least to some extent, why not all RhD negative women with an RhD 
positive fetus become sensitised during pregnancy.  Also, the gender of the fetus appears to have an 
influence with male fetuses representing a higher risk of sensitisation [24]. 
 
The introduction of postpartum (post-delivery) prophylaxis achieved a reduction of sensitisation events to 
1%.  Introduction of routine antenatal anti-D prophylaxis (RAADP) at weeks 28-30 has further reduced 
the incidence rate to less than 0.2%, in other words, the number of women sensitised in the UK has 
reduced from 1,000 per year to less than 140 [17].  In the US and Canada, RAADP at 28 weeks’ 
gestation has similarly reduced the incidence of sensitisation from around 1% to 0.13% of births to RhD 
negative women [16].  
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However, even if sensitisation does occur this will not necessarily lead to haemolytic disease of the 
fetus/newborn (HDN).  Therefore, the consideration of a policy of routine antenatal anti-D prophylaxis 
has prompted several researchers to estimate the measurable benefit of prenatal anti-D and its impact 
on incidence of HDN as well as sensitisation risk.  
 
2.1.3  Evidence on haemolytic disease of the fetus/newborn (HDN)  
 
Changing incidence of HDN 
Before any form of prophylaxis was available, HDN affected 1% of all newborns of second pregnancies 
to RhD negative women in England and Wales, and even more in subsequent pregnancies.  In the mid 
1950s, HDN was responsible for one death in 2,180 births in England and Wales.  Anti–D prophylaxis 
(postpartum) was introduced in the late 1960s, and reduced the number of deaths to one tenth of that 
figure [1].   In the 1970s and 80s, other potentially sensitising events, for instance abortion and ectopic 
pregnancies, were included in the guidelines ([29] and references therein) with the introduction of 
antenatal anti-D prophylaxis (AADP).  Its usage also lowered the incidence of RhD sensitisation to 1% 
([17] references therein).  Overall, these changes in guidelines have produced a reduction in deaths due 
to HDN from an initial 310 per year in the mid 1950s to an average of 18 in 1994-1999 (excluding fetal 
losses which occur before 20 weeks of gestation) [1].  
 
But continuing cases of sensitisation and HDN in the 1990s prompted the introduction of routine 
antenatal anti-D prophylaxis (RAADP) for all RhD negative women prenatally, reducing sensitisations 
even further to approximately 0.1% [17].  For example, it was reported that about 625 women still 
continued to become sensitised each year in the UK [1].  This meant that 7 out of 1,000 live born infants 
were delivered by sensitised mothers [18] mainly due to failure of administration of anti-D either post-
partum or prenatally after high risk events such as miscarriage, or due to undetected small prenatal 
bleeds or due to other red blood cell antigens that can cause sensitisation for which anti-D 
immunoglobulin is ineffective.  As a result, it was calculated that 25-30% of fetuses and newborns in 
second pregnancies of sensitised women would have some degree of haemolytic anaemia and another 
20-25% would be hydropic with a significant minority resulting in death.  It was estimated that this 
translated into at least 30 fetal deaths, stillbirths, neonatal and post-neonatal deaths due to HDN in 
England and Wales [1].  The total number of perinatal deaths per annum is approximately 4,482 (2001 
figures). 
 
Although the number of deaths due to HDN is relatively small, underreporting of HDN incidences should 
also be taken into consideration [19].  For example, in Scotland an underreporting of mortality from RhD 
haemolytic disease has been identified, attributed to the fact that certification data initially excluded 
stillbirths before 28 weeks. A corrected figure for the number of actual deaths due to HDN was used 
to support the introduction of RAADP in Scotland.  
 
Morbidity and mortality associated with HDN 
HDN is a severe disease which is recognised all over the world.  Reports of its epidemiology have been 
published in a number of different countries.  Chavez et al. [20] in 1991 commented that Rh HDN 
continued to contribute significantly to infant morbidity and mortality in the USA.  Despite the availability 
A Review of Evidence on Non-invasive Prenatal Diagnosis (NIPD):                                                              Background                                     
Tests for Fetal RHD Genotype 
 
 
 18
of preventive measures, the incidence rate in the USA in 2002 was estimated to be about one to six 
cases in every 1,000 total live births [21]. 
 
Likewise, in the 1990s it was reported that HDN was still associated with significant morbidity in Northern 
Ireland.  In a 3-year period (1994-1997), 78 out of 130 babies delivered from 124 sensitised women 
were affected by rhesus sensitisation.  Two stillbirths and one neonatal death were reported among the 
affected offspring.  Another two infants had severe neurodevelopmental delay [22].  
 
A slightly more recent report addresses the epidemiology of HDN in the Netherlands.  This presents the 
results from the screening of 2,392 pregnant women for irregular erythrocyte antibodies over a 3-year 
period (1995-1998).  Antibodies were found in 65 women who were bearing 30 antigen positive children.  
12 of these children developed clinical symptoms of HDN, intrauterine death was diagnosed once and 
one child died immediately after birth.  One child had signs of hydrops fetalis and two required exchange 
transfusion.  Phototherapy and blood transfusion were given to 7 babies.  Various antibodies can cause 
HDN (e.g. anti-D, anti-Kell, anti-c, anti-E).   Most cases of HDN were caused by anti-D, anti-Kell and 
anti-c [23]. 
 
The survival rate of fetuses with hydrops was investigated by Van Kamp et al. [25] who determined the 
overall survival rate to be 78%.  Mild hydrops can be reversed with adequate treatment (intrauterine 
transfusion) which increases the chance of survival.  Early diagnosis of fetal anaemia and referral to a 
specialised centre are important and enable the start of intrauterine treatment early.  
 
An interesting study reported in 1999 that male fetuses are more severely affected by maternal 
sensitisation than female fetuses.  Perinatal mortality is three times higher in male fetuses, they require 
more transfusions and have a greater likelihood of developing hydrops fetalis, a major condition of HDN 
[24]. 
 
The papers above show that even though measures to avoid sensitisation are available, HDN has not 
been eradicated.  NIPD RHD genotyping as an addition to existing strategies to prevent sensitisation 
and, therefore, HDN, is a promising development.  Many countries have centralised the management of 
RhD affected pregnancies to guarantee training opportunities and maintenance of expertise [22].  This 
could also assist in the implementation of RhD NIPD for sensitised women, although RAADP would be 
provided via local maternity services.  The findings of the epidemiological research need to be taken into 
account in any further studies.   
 
2.2  Current Prenatal Testing and Clinical Management 
 
Service provision for prenatal care varies from country to country in Europe.  Three recent articles have 
reported that differences result partly from variations in the structure of antenatal care in different 
countries, and also the fact that there are different national guidelines, and different ways of providing 
healthcare.  Investigating 25 EU member states Bernloehr et al. [89] reported that 20 have national 
guidelines for antenatal testing.  The content of the guidelines, however, varies in respect of the types 
and number of tests recommended within the antenatal care plan and how often individual tests ought to 
be carried out.  The number of prenatal visits also varies, ranging from a minimum of 4 in Italy to a 
maximum of 12 in the Netherlands and Germany.  The time of the initial visit is also reported to vary 
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from 6 weeks to 16 weeks of gestational age [90].  A survey of the organisation of antenatal care 
services also reveals differences in the main care provider, financing, main site of care, integration with 
other services and uniformity of the organisation of prenatal care [91].  These factors mean that it is 
impossible to describe a uniform plan of care in uncomplicated pregnancies applicable to all European 
countries, let alone for pregnancies with complications.  Furthermore, differences also exist within 
individual countries due to regional service provision, unequal access to service by different groups of 
the population and economic reasons.  Thus, the possible integration of NIPD into current EU member 
states' healthcare systems can only be discussed in general terms, until more detailed national 
information is available. 
 
2.2.1  Routine antenatal anti-D prophylaxis (RAADP)  
 
It is also evident that variations in services for RhD negative pregnancies currently exist in EU states.  In 
the 1960s, post-partum anti-D prophylaxis was introduced in various developed healthcare systems, 
administered to RhD negative women after delivery of an RhD positive baby ([17] references therein).  
Routine antenatal anti-D prophylaxis (RAADP) is usually administered at about 28 weeks of pregnancy.  
This date is chosen because prophylaxis is effective for up to 12 weeks.  Protection is required primarily 
to cover the third trimester, until the delivery of the baby, because small amounts of fetal blood will 
usually not stimulate the maternal immune response since fetal cells are usually rapidly cleared by the 
maternal system.  Sensitisation is most likely to occur in the third trimester when the risk of fetomaternal 
haemorrhages increases to 45% [30].  
 
But there are several disadvantages to a policy of routine antenatal anti-D prophylaxis.  Firstly, a policy 
of RAADP, in addition to AADP and post-partum anti-D, requires an up to fourfold increase in anti-D 
production [31] which could cause supply issues.  This may be the reason why RAADP introduction has 
been restricted to only a few countries, combined with the Cochrane Database reporting a large 'number 
needed to treat'. Crowther and Middleton [32] calculated that 213 women need to be treated with 
prenatal anti-D in order to avoid one case of sensitisation.  This calculation is based on all RhD negative 
women receiving prenatal anti-D because there was no method available to identify the 60% of women 
with RhD positive babies.  Consequently, this number could be reduced to about 128 with the 
implementation of NIPD RHD genotyping to target RAADP. 
 
Secondly, safety issues have been linked with the administration of serum derived anti-D IgG.  The 
possibility remains of infectious agents being present for which there is no test available, or available 
tests are not sufficiently sensitive e.g. variant Creutzfeldt-Jakob disease.  A specific instance of 
transmission of infection relates to the use of pooled plasma for anti-D production in Ireland where 
pregnant women were infected with hepatitis C by anti-D IgG between 1991 and 1994 [31]. 
 
Thirdly, there may be ethical concerns about boosting donors to maintain high-titre polyclonal anti-D. 
This deliberate immunisation may result in complications in future therapeutic transfusions due to 
platelet and leukocyte antibodies or antibodies to non-D erythrocyte antigens [31]. 
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2.2.2  Variation in clinical management of RhD negative pregnant women in different 
countries 
 
As far as current services for RhD negative pregnant women are concerned, all member states offer 
post-natal anti-D prophylaxis; this involves prenatal blood typing of pregnant women and a post-natal 
blood-typing test for the baby if the mother is RhD negative.  Similarly, most countries offer AADP 
(antenatal anti-D prophylaxis) following potentially sensitising events (e.g. amniocentesis, abortion) 
although guidelines may vary.  In contrast, to date not all EU countries have implemented RAADP and 
even within these countries access to this service may not be universal.  Finally, even fewer countries 
have introduced NIPD RhD tests into routine practice.  Where such tests are currently used, they are 
routinely utilised in the management of sensitised women. 
 
Even if a RAADP policy exists in a country, not all women will receive prenatal prophylaxis.  One reason 
may be that the adherence to guidelines is patchy. For example, it has been reported for England and 
Wales that only 30% of hospitals offer the service of RAADP [7].  A second reason may be that the 
RAADP policy implemented does not apply to all women.  In the Netherlands, for example, only 
pregnant women with no living child (about 16,000) received prenatal prophylaxis due to the limited 
supply of home produced anti-D; but 6,400 of these women with an RhD negative fetus receive it 
unnecessarily [11].  NIPD has the potential to resolve these issues.  For example, identification of RhD 
negative women with an RhD positive fetus during pregnancy by NIPD might increase the number of 
hospitals providing RAADP to women in England and Wales, making routine prenatal prophylaxis more 
readily achievable and approaching the theoretical benefit of RAADP.  Similarly, in the Netherlands the 
point is made that 40% of anti-D can be saved by identifying the 40% of women who carry an RhD 
negative fetus, and this could then be offered to multigravidae, who are currently not included in the 
RAADP policy.  In the Netherlands, prenatal prophylaxis provided to all RhD-negative women might 
reduce the incidence of new Rh-immunisations in multiparous women from the current 100-125 to 50-70 
new cases per year.  Because one out of three multiparous women will have another child and 71% of 
these children will be RhD positive, it has been estimated that around 12 new cases of RhD HDN could 
be prevented by extending RAADP to these women [11]. 
 
2.2.3  Future improvements in management of RhD negative pregnant women 
 
Likely future improvements to the management of RhD negative women are limited.  There is currently 
no therapy available to target the maternal immune response in these women.  Once sensitisation has 
occurred, surveillance and treatment, for instance using intravascular transfusion techniques, is the only 
option available even though selective administration of maternal intravenous immune globulin and 
maternal sensitisation to paternal leukocytes have been discussed [21, 26, 27].  The latter is based on 
the postulation that maternal antibodies to paternal leukocyte antigens that are shared with the fetus 
cross the placenta and inhibit fetal monocytes, thereby preventing red blood cell destruction [26]. This 
lack of therapy is the main reason why attention remains directed towards the prevention of 
sensitisation.   
 
NIPD, therefore, has the potential to complement and improve prevention in countries which have 
introduced RAADP. The alternative to NIPD is to continue with the unchanged, current policy of giving 
anti-D to all RhD-negative pregnant women during the third trimester. 
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But in spite of the published evidence that sensitisation is lowered by prenatal anti-D IgG, the actual 
benefit of prenatal prophylaxis RAADP remains debatable.  It has been remarked that the observed 
decline in incidences is partially attributable to smaller family sizes since HDN increases in severity with 
increasing birth order.  In 1996, the US Preventive Services Task Force argued that the impact of 
prenatal prophylaxis on the incidences of HDN was relatively small and with that, was 16 times less 
cost-effective than a postpartum prophylaxis only policy [16]. 
 
2.2.4 Current and future RhD NIPD testing  
 
Use of NIPD tests in sensitised RhD-negative pregnancies 
RhD NIPD is currently only used routinely in the management of a defined population - sensitised 
women.  For example, in the UK the International Blood Group Reference Laboratory (IBGRL) in Bristol 
offers a fetal RHD genotyping service to obstetricians managing the pregnancies of alloimmunised 
pregnant women via their local blood centre.  Blood samples from pregnant women who have tested 
RhD negative during routine prenatal care and positive for antibodies is genotyped (NIPD) for the fetal 
RHD status in order to decide on further treatment. 
 
NIPD RHD genotyping has the potential to replace invasive testing methods like amniocentesis or 
chorionic villus sampling if these are used for the sole reason of determining the fetal RHD genotype.  
This would appear to be highly desirable because invasive tests are associated with an increased risk of 
miscarriage as well as an increased incidence of gestational maternal immunisation by inducing 
fetomaternal haemorrhages in 17% of cases [68, 69].  On the other hand, there is some indication that 
the perception of end-user might vary slightly.  A survey of high-risk pregnant women about to undergo 
invasive testing revealed that these women see the NIPD test as part of a stepwise testing strategy in 
which the non-invasive test results will help women to make a decision on whether invasive testing is 
desirable [38].  
 
When combined with serologic methods, RH molecular testing is already an important tool to resolve 
discrepancies and ambiguous typing results in transfusion medicine.  This should encourage the 
establishment of RHD markers for RhD NIPD.  For fetal RhD testing and prediction of HDN, samples of 
the mother and father need to be analysed serologically and molecularly [14]. 
 
Use of NIPD tests in routine RhD-negative pregnancies 
Currently, no country routinely uses NIPD to decide whether non-sensitised women need routine 
antenatal anti-D prophylaxis or not.  At present, this is being considered for introduction in the 
Netherlands as a universal policy with all RhD negative women tested.  Furthermore, there is the 
possibility that if introduced in Germany women would be given the choice between prophylaxis at about 
28 weeks of pregnancy or NIPD RHD genotyping [74]. 
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Timing of NIPD tests 
If NIPD were to be used to target RAADP, it is sufficient to carry out the test in the third trimester.  
However, for the management of sensitised women early identification of the fetal genotype would be 
advantageous.  There are, therefore, clinical advantages in being able to perform the test at a woman's 
booking prenatal visit, usually in the first trimester, rather than in the second half of pregnancy [28].  
However, at present testing women in the second trimester increases accuracy rates (see section 4.2). 
 
 
2.3 Other Technologies under Development 
 
Since any new policy involving NIPD use to target RAADP will be introduced over a number of years (3-
6 years), it is also important to consider emerging alternative or competitor technologies and their likely 
impact on the perceived value for money of RhD NIPD over this period same period. 
 
2.3.1 Recombinant anti-D immunoglobulin 
 
Due to the potential risks associated with the supply and safety issues of existing, serum-derived anti-D 
products (see section 2.2.1), a potential new product which may be of relevance is recombinant anti-D.   
This bio-engineered product may resolve supply and safety issues of human anti-D used for prevention 
of sensitisation and HDN.  However, it is unclear when the product is likely to reach the market. 
 
In order to gather information on this, European and Australian companies involved in the development 
of recombinant anti-D were identified and approached for information [33, 34, 35, 36].  The information 
provided indicates that dosage and treatment regimens are expected to be similar to existing anti-D 
products, potentially providing an alternative safe and steady supply of anti-D.  The companies 
themselves report excellent early clinical data and a more cost-effective product although no peer-
reviewed publications are available.  They also appear optimistic that their product will make it to the 
market in the near future (3 years). 
 
Scientific experts we surveyed do not share the optimistic views of the biotechnology companies.   
Experts commented that it is particularly difficult to produce a recombinant anti-D since the RhD antigen 
is known to express several different antigenic epitopes.  For a complete pattern of reactivity, and in 
order to be successful in prophylaxis, all epitopes need to be included.  In addition to antigen specificity, 
antibodies also need to be able to interact with effector cells in order for IgG coated RBCs to be cleared 
from the maternal circulation [31].  
 
Dosage and treatment regimens may also need to be adapted from the regimens currently used for 
existing anti-D products.  For example, in 2000 Miescher et al. [37] published the result of a recombinant 
monoclonal anti-RhD antibody with a novel reactivity pattern which was expected to meet the stringent 
regulatory and safety requirements demanded for the use of recombinant products in humans.  Testing 
the new product, it was discovered that one testing strategy required more recombinant anti-D than with 
chromatographically purified rhesus (D) immunoglobulin - Rhophylac [17] to attain the same activity.  
The relevance of these quantitative in-vitro differences for clinical efficacy needs to be addressed and 
might be contradictory to the claim that dosage and treatment regimens are expected to be the same 
with both types of anti-D antibodies. 
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It appears that, at this stage, the performance of monoclonal anti-D antibodies in various in vitro assays 
cannot be readily transferred to predict in vivo efficacy [31].  Furthermore, there are obvious issues with 
the public perception associated with recombinant anti-D IgG.  Administering a biotechnology product to 
young healthy pregnant women has been seen as a high commercial risk and it has been suggested 
that people’s judgement of relative risk needs to change for patients to make a reasonable decision on 
the potential risks from biotechnology products as opposed to blood products [31].  These views contrast 
with the over optimistic statements and timeframes of the biotechnology companies. Further information 
and evidence on this issue are currently being collected. 
 
2.3.2 Peptide immunotherapy 
 
Another promising alternative technology which would avoid the risks associated with blood products 
entirely, is tolerance induction to the RhD antigen by mucosal delivery of synthetic RhD peptides [82].  
This would make women “immune” to sensitisation.  Mucosal administration of peptides has been 
previously used to induce systemic tolerance to antigens in different models [82] and acts by active 
immune regulation.  Hall et al. [82] demonstrated that the activation of a specific immune response can 
be prevented by the manipulation of T-helper (Th) cell recognition of the RhD protein in a transgenic 
mouse model.  
 
Four dominant RhD peptides, which stimulate Th cells in alloimmunised RhD-negative donors, have 
been tested for their tolerogenic potential in a humanised mouse model, transgenic for the molecule 
conferring RhD specificity of Th cells.  Hall et al. [82] report that these 4 peptides induce tolerance when 
the RhD peptide was administered 2 weeks prior to RhD immunoglobulin challenge.  This study shows 
that humanised mice can make IgG antibodies specific for the RhD protein and that this can be 
prevented by nasal administration of synthetic peptides containing dominant Th epitopes.  This research 
represents an important first step in the development of immunotherapy for HDN and would provide 
several advantages in relation to passive RhD immune globulin, which is transient and needs to be 
administered after each exposure to the antigen.  Furthermore, in the latter case the antibody dose 
needs to be optimised to match the size of the feto-maternal haemorrhage for maximum efficacy.  
 
The study of Hall et al. [82] provides the basis for further research into the mechanism of tolerance 
induction, and phase-1-trials of peptide immunotherapy to prevent anti-RhD responses in humans are 
currently being planned.  This product is unlikely to reach the market in the medium-term future (3-6 
years). 
 
2.3.3 Preimplantation genetic diagnosis 
 
For the small number of severely sensitised women, preimplant genetic diagnosis (PGD) may be 
considered rather than NIPD in a natural pregnancy.  In 1995 single cell analysis of the RhD status was 
carried out on cultured lymphoblasts.  It was suggested that this technique can be used in PGD in 
sensitised women for the prevention of HDN [83].  Avner et al. [84] determined the RhD status of two 
embryos for the selective transfer of RhD negative embryos in a family of a sensitised woman and a 
heterozygote partner.  Typing resulted in the conclusion that both embryos were RhD negative.  
However, the result could not be confirmed since pregnancy was not achieved. 
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In 2005 Seeho et al. [85] reported the first case of an unaffected RhD negative baby being born to an 
RhD-alloimmunised mother using preimplantation diagnosis.  A couple with two children, the second 
child affected by HDN, was counselled that RhD screening prior to implantation using PGD could allow 
selective transfer of only RhD negative embryos.  Two out of twelve embryos were typed RhD negative.  
Transfer resulted into a clinical pregnancy and RhD negativity could be confirmed postnatally [85]. 
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3  NIPD TEST DEVELOPMENT AND PERFORMANCE 
 
 
3.1 Emergence of Non-invasive prenatal diagnosis based on free fetal DNA 
 
In the middle of the 1990s, fetal cells [4] and free fetal DNA in maternal circulation [5] were recognised 
as a potential route for non-invasive prenatal diagnosis.  Scientists believed that it should be possible to 
detect fetal cells in maternal blood as early as four weeks of gestation when the fetal heart commences 
beating and the villi are vascularised.  The earliest detection so far is around week 4 and 5 using PCR 
based amplification of Y-specific DNA sequences [6].  The number of fetal cells in maternal circulation 
increases with gestation age, but they are still very rare even in late pregnancy [6].  There are also 
potential problems associated with the reported persistence of fetal cells from previous pregnancies 
which can lead to false positive results [8].  While the work on the detection of fetal cells in maternal 
circulation continues, several laboratories are now working on the evaluation of fetal DNA extracted from 
maternal plasma first discovered in 1997 [5]. Fetal DNA may arise directly from various sources (the 
syncytiotrophoblast, from shed apoptotic cells or result from lysis of fetal cells transferred across the 
placenta [9]) and can be detected as early as 7 weeks [10].  Rapid removal of fetal DNA from the 
maternal circulation suggests that it might be less susceptible to false positive results than using fetal 
cells [9]. 
 
The amount of free fetal DNA in maternal blood is a limiting factor for most forms of fetal genotyping 
(including fetal RhD).  While fetal DNA amounts increase during pregnancy [10], there are notable 
variations from pregnancy to pregnancy and also there are day-to-day variations which would have to be 
taken into consideration since certain non-invasive tests need to be performed at specific gestation age 
to bring useful information early enough in pregnancy.  To date, fetal DNA typing has been limited to the 
diagnosis of mutations of paternal origin, i.e. cases in which a specific and unique gene from the father 
is sought (autosomal dominant disorders and X-linked disorders, in which the father and mother carry 
different identifiable mutations).  Fetal cells lack nuclei and therefore do not allow standard prenatal 
karyotyping which would be required to detect all fetal chromosome disorders [9].  However, fetal DNA 
typing is useful for detecting some genetic characteristics and the D gene specifically.  
 
The development of assays for non-invasive RHD genotyping first became feasible once it was possible 
to detect non-invasively the SRY gene (sex-determining region of the Y chromosome) which is found on 
the Y chromosome.  With the growing understanding of the molecular basis of the Rh blood group 
system and advances in determining fetal RhD blood group status using PCR on amniotic or chorionic 
villus cells, the development of assays for non-invasive RHD genotyping became possible. 
 
3.2 Emergence of RhD NIPD technology 
In 1994, Lo et al. [39] reported the investigation of fetal RhD status in three sensitised RhD negative 
women by non-invasive means demonstrating the feasibility of fetal RhD sequence detection from 
circulating RhD-positive fetal cells.  This was the beginning of NIPD RHD genotyping. 
 
Following the discovery of free fetal DNA in the maternal circulation [5], this (rather than fetal cells) 
became the material of choice for non-invasive fetal RHD genotyping because RhD positivity or 
negativity depends on the presence or absence of one single gene.  Only one of the studies we 
identified did not exploit the presence of free fetal DNA but used mRNA from erythroblasts instead.  
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Cunningham et al. [6] postulate three advantages in using mRNA.  Firstly, using mRNA reduces the 
likelihood of contamination because it is more sensitive to degradation.  Secondly, presence of a certain 
mRNA is limited to the cells that produce it which are, in this case, fetal erythroblasts?what does this 
mean?.  Finally, mRNA is present in multiple copies.  It was also suggested that reverse transcription 
PCR might be a more sensitive alternative to standard PCR. 
 
Extracting DNA from either serum or plasma does not seem to have a significant influence on diagnostic 
accuracy in fetal sexing, the early application of NIPD [40].  Results of earlier studies, however, suggest 
a preference for plasma [41, 42].  Tufan et al. [40] reported slightly higher accuracy when using plasma 
for sex genotyping rather than serum.  This might be explained by a concentration difference of cell free 
fetal DNA in maternal plasma versus serum [10].  This tendency to prefer plasma was carried through to 
RhD NIPD.  In general plasma is the favoured material for DNA extraction even though some research 
groups have used serum and one group whole blood.  Turner et al. [8] have argued that when using 
whole blood, the sensitivity of the assay is increased because it represents a larger volume of blood for 
DNA extraction.  But Finning et al [43] replied to this statement by pointing out that plasma contains a 
higher proportion of fetal DNA than the cellular fraction of maternal blood.  Furthermore, the background 
of maternal DNA is reduced when using plasma, which increases sensitivity of the test.   
 
Randen et al. [46] have examined the impact of different temperatures and duplexing (i.e. simultaneous 
amplification of markers of the RHD and SRY genes in one test tube) on the test result and reported that 
temperature had an impact on the performance of DNA extraction.  There was a statistically significant 
reduction of fetal DNA in samples stored at room temperature.  Duplex PCR of RHD and SRY reduced 
the sensitivity for SRY gene amplification and it had to be concluded that this duplex PCR was not 
suitable for routine analysis.  Zhong et al.  [47], on the other hand, have reported the same efficiency 
when determining multiple fetal loci from free fetal DNA.  A further factor influencing test performance 
appears to be the time that samples are stored.  It has been advised recently that samples need to be 
processed as quickly as possible [48]. 
 
3.3  Papers Reporting Studies of RhD NIPD Diagnostic Accuracy 
 
Altogether 21 papers were examined and data extracted (see Annex 2).  A STARD score was assigned 
to every paper in the following areas. 
 
3.3.1  Mesh headings 
 
Articles were generally poorly indexed.  Only 3 early articles identified the paper as a study on diagnostic 
accuracy using the recommended MeSH heading Sensitivity and Specificity.   
 
3.3.2  Research questions or study aims 
 
When stating the research questions or study aims, papers also did not refer to sensitivity and 
specificity.  Furthermore, when reporting study findings (see Annex 2), ‘accuracy’ and ‘detection rate’ 
were more frequently used expressions.  Genotypic and phenotypic sensitivity/specificity could not be 
distinguished in most papers under these two specified headings. The majority of studies that aimed to 
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report on test diagnostic accuracy were actually scientific studies exploring the new test and testing its 
limitations. 
 
Finally, occasional use of terms such as sensitivity and specificity did not equate well with the accepted 
definitions of test sensitivity and specificity.  Authors appeared to use different definitions which meant 
that where such results were presented they were not directly comparable.  This fact complicated the 
assessment of these papers against the checklist.  According to the STARD checklist, the identified 
studies were for that reason generally either poorly designed or poorly reported. 
 
3.3.3 Study populations 
 
When presenting the study methods and reporting results, papers were generally found not to describe 
the study population in depth, including whether a consecutive series of participants was used, the 
beginning and end dates of recruitment, or the recruitment centres used.  Reporting of the number of 
participants satisfying the inclusion criteria who did or did not undergo the index tests and/or the 
reference standard; and an explanation of why participants failed to receive either test were rarely 
covered. 
 
The number of samples tested in the studies reflects the movement in the progress of a new technology.  
Early studies used a smaller number of samples, rarely exceeding 100 pregnant RhD negative women.  
Promising results from these studies prompted researchers to be more positive about the potential 
transition into clinical practice of this non-invasive technology, consequently establishing larger trials.  In 
2004, a French study investigated the feasibility and accuracy of large scale RhD fetal diagnosis, 
including 893 RhD-negative women [44].  In 2005, Minon et al. [87] reported the results of 223 samples 
evaluating two years of routine practice of RhD NIPD in Belgium.  The largest trial to date has been 
conducted in the Netherlands.  An abstract published in 2004 describes a Dutch study which recruited 
2,543 D-negative pregnant women [49].  The final report is currently being finalised [11].  This was the 
first large scale trial to provide evidence for clinicians and, very importantly, health care funders on the 
real potential of the new test in use.  
 
3.3.4  Test method 
 
Reference standard 
The reference standard used in studies varies.  In cases where invasive procedures were carried out, 
fluid or cells from amniocentesis or chorionic villus sampling were used for PCR and the results 
compared with those of the index test.  In all other cases, postpartum serological blood typing was used 
as the reference standard for the validation of the results.  Data collection was generally planned before 
the index test and reference standard were performed (prospective studies). 
 
Technical specification of material and methods  
Description of the technical materials and methods was generally well covered in the studies throughout.  
Quantitative real-time fluorescent PCR was the method of choice.  Although the expense of the 
equipment  may limit use in a routine setting [40].  Real-time PCR, in contrast to conventional PCR, 
collects data in the exponential growth phase of the reaction which is the most specific and precise 
phase of the reaction.  Traditional PCR, however, is measured at the end-point requiring post PCR 
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processing.  This allows real-time PCR to be more precise and more sensitive and it can be automated.  
Fluorescence dyes attached to a probe are added to the reaction mix which change their fluorescence 
either in intensity or colour as the PCR reported in 2004 product is synthesised.  The increase in 
fluorescence is directly proportional to the number of product copies generated and can be measured 
while amplification is occurring.  
 
An attempt to compare conventional with real time PCR discovered no greater sensitivity when using 
real time PCR but a greater specificity [44].  Furthermore, real time PCR is less time consuming and 
possesses an extra level of protection against contamination.  At the same time, conventional PCR was 
thought to be unsuitable for diagnostic use [45].  But Tufan et al reported in 2005 that optimisation of a 
multiplex PCR could disprove this attitude towards conventional PCR, and this would be a manageable 
task for any clinical laboratory where conventional PCR is available [40].  However, conventional PCR 
has not prevailed and quantitative real-time PCR is the method of choice in the majority of published 
studies.  The first report of its automation was published in 2004 by Van der Schoot et al. [49]. 
 
Besides the choice of material (see 3.2 above), other factors have been shown to influence the success 
of PCR-based non-invasive prenatal genetic diagnosis.  DNA extraction methods and PCR cycle 
numbers, as well as the risk of contamination, are major success-limiting factors and therefore need to 
be optimised.  It has been suggested that the QIAamp DNA Blood Mini extraction kit, in combination with 
a 40-cycle PCR, gives the optimum results.  It has also been suggested that the risk of contamination 
can be reduced by using ready-to-use PCR mixtures which contain all components therefore reducing 
necessary pipetting steps to a minimum [40].  
 
When measurements were taken 
The time in pregnancy at which samples were taken varied between studies. The Czech group 
Hromadnikova et al. [65] tested mainly women in the second and third trimester, while populations of 
other research groups covered all trimesters [60, 44, 46, 67, 10].  Targeting a specific category of 
pregnant women, i.e. women about to undergo invasive procedures or blood samples taken for maternal 
triple serum screening, predetermined the time of testing to the second trimester in two studies [47, 9].  
Women undergoing genetic counselling were restricted to first trimester pregnancies in one study [63].  
Turner et al. recruited women before 20 weeks gestation, bearing in mind the likely point of time of the 
first prenatal visit.  Similarly, Gonzalez-Gonzalez et al. [48] tested 11 to 16-week pregnant women. 
 
In the Netherlands, where the reduction of anti-D application in RAADP seems to be the driving force for 
adoption into clinical practice, early genotyping was not an issue.  Here, women that were 28-30 weeks 
pregnant were tested. 
 
Other descriptors 
The number, training and expertise of the people carrying out and reading the tests was poorly reported.  
The 'masking' of test readers was specified in only one paper i.e. readers of the index test and reference 
standard were masked to the result of the other test.  Definitions and rationale for the units, cut-offs 
and/or categories of the results of the index test(s) and the reference standard were not applicable in 
RHD genotyping since this is a qualitative test.  Test reproducibility was not reported as such, but the 
number of replicates required per sample for an accurate prediction of fetal RHD status was discussed 
(see section 3.3.7).  
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3.3.5  Test results 
 
The variations in sample characteristics and test parameters reported in papers complicated the 
evaluation and comparison of study quality and the generalising of results.  Reported test ‘accuracy’ 
ranged from 75% to 100%. 
 
Time interval from index test & distribution of severity of disease 
The time interval from index test to reference standard was only reported indirectly when stated that the 
reference standard was the postpartum serological blood test.  This STARD item, and details of any 
treatments administered between, are not relevant to RhD status, which cannot change.  Similarly the 
distribution of severity of disease in those with the target condition; and other diagnoses in participants 
without the target condition is not relevant in RhD NIPD because presence and absence of a gene is 
tested for. 
 
Cross tabulation of results 
Most studies reported a cross tabulation of study outcomes of the index test and the reference standard, 
and discrepancies between the two.  However, some studies did not include indeterminate results in the 
calculation of accuracy, i.e. cases in which a woman is suspected to have a non-functional gene [60, 
44].  This will influence the reliability of the study results.  Studies also did not generally report how 
missing responses and outliers of index tests were handled. 
 
Measures of statistical certainty 
Methods for calculating or comparing measures of diagnostic accuracy, and the statistical methods used 
to quantify uncertainty, were not described in any study.  Measures of statistical certainty/uncertainty 
e.g. 95% confidence intervals, were not reported by any study.  In fact, as well as no attempts to 
minimise bias by masking of test readers, the absence of any statistical methods to estimate uncertainty 
were two consistently weak points of these studies.  Estimations of variability of diagnostic accuracy 
between subgroups of participants, readers or centres were also not reported in any study. 
 
Other 
Finally, the STARD item relating to reporting of adverse events of index tests and reference standard 
was not relevant in the context of RhD NIPD. 
 
3.3.6  Markers for RhD NIPD 
 
For RHD genotyping, regions of highest divergence between the RHD and RHCE genes are required for 
NIPD.  These were reported in 1993 to be located in exons 4, 5, 7, and 10 as well as intron 4 which has 
a 600bp deletion in the RHD gene in contrast to the RHCE gene [57].  But gene variants in the RHD 
gene place some doubt on the accuracy of a PCR reaction using only one primer pair.  This led Aubin et 
al. [50] in 1997to evaluate and compare 4 different PCR methods of RHD gene detection using different 
primer sets.  Blood samples of blood donors, including a number of different gene variants and amniotic 
fluid from 92 fetuses, were collected for the study.  The authors reported that the method using exon 7 
was the most sensitive out of the four (exon 10, exon 7, exon 4, intron 4). 
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Using blood samples from RhD-negative pregnant women, only one method (exon 10) gave 6 false 
positive results in Caucasians.  A much higher false positive rate was obtained if the blood samples 
were of African or Asian origin.  Three of the four methods were reported to have the potential to give 
false negative results when some rare variants were examined.  These are clinically more relevant than 
false positives.  The methods were those using exon 7, 4, and intron 4.  From these results, Aubin et al. 
[50] recommended as a minimum that an assay for routine use be based on two methods which should 
include use of exon 7 because this is the most sensitive.  This combination would be able to detect all D 
variants investigated.  However, sensitivity of exon 10 could be improved by changing one RHD 
sequence specific oligonucleotide.  In 2004, this new exon 10 PCR was reported to reach the same 
sensitivity as exon 7 PCR [44]. 
 
Applying this approach for non-invasive RHD genotyping, Johnson et al. [45] in 2003 and Hromadnikova 
et al. [58] in 2005 reached the same conclusion about the usefulness of using at least two RhD specific 
products for amplification in order to increase accuracy but the markers were not consistent. Exons 7 
and/or 10 were the most commonly used markers for RHD genotyping in the studies under investigation.  
Exons 6 and/or 4 and 5 have been included to prevent positive results if a non-functional gene 
(RHDΨ)was present [28, 87].  The Czech group included two different markers, namely intron 2 and 
exon 5, in order to additionally genotype for the closely related RHCE gene [59]. 
 
3.3.7  Number of repeated measurements required per specimen 
 
In addition to positive controls, replicates (i.e. repeated measures) are needed for an accurate 
prediction of fetal RHD status [67] and to ensure the reliability of test results.  Between two and seven 
replicates were reported in the studies reviewed.  However, some studies either did not include 
replicates or did not report them.  Conversion of replicate outcomes into an overall test result was 
handled differently across the studies.  Hromadnikova et al. [65] considered a sample to be positive if at 
least 1 out of 5 replicates was positive.  In contrast, Legler et al. [64] demanded at least 2 positive 
results out of 4 replicates for an overall positive test result.  Similarly, Clausen et al. [88] only considered 
a sample as positive when at least two replicates out of 4 were positive for two different exons.  A 
Norwegian study has reported the discrepancy between index test and reference standard in two 
different ways; considering all replicates in one analysis and demonstrating a reduction in false result 
when only requiring one positive replicate for an overall positive result [46].  
 
Comparing conventional with real time PCR, Rouillac et al. [44] only classed a sample positive if both 
assays reported a positive result of a least one of the two markers, i.e. exon 7, while Johnson et al. [45] 
used three markers and reported their specificity and sensitivity in case of concordance of at least two 
exons. 
 
3.3.8 Performance in twin pregnancies 
 
Multiple pregnancies have been investigated in 5 reports [28, 44, 59, 86, 87].  Pregnancies with at least 
one RhD positive fetus could be successfully identified as RhD positive in 3 studies [59, 86, 87].  The 
correct identification of the other fetus(es) is of less importance since prophylaxis needs to be 
administered in the case of one positive fetus.  However, two studies reported discrepancies between 
genotyping and amniocentesis.  In one case RhD positive DNA was amplified at 13 weeks gestation, 
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while genotyping of amniotic cells resulted in a negative result for both fetuses [86]. RhD negativity was 
confirmed by postnatal serology.  Since this pregnancy was the result of IVF, it was suspected that a 
third non-evolutive RhD-positive embryo could have caused the result.  In contrast, Finning et al. [28] 
correctly identified at least one RhD positive fetus by genotyping, while amniocentesis identified two 
RhD negative fetuses.  At birth, serologic tests confirmed that one boy was indeed RhD positive and it 
was concluded that amniotic fluid for amniocentesis must have been drawn from only one amniotic sac. 
 
3.4 Results Obtained in Multiple Laboratories and Quality Assurance 
 
To date, only a limited number of inter-laboratory studies have been carried out in order to assess the 
feasibility of NIPD delivery in the service setting.  In 2004, five participating centres in a National Institute 
of Child Health and Human Development Consortium developed and validated a standard protocol for 
DNA extraction for fetal DNA amplification [71].  Using the SRY gene, variations in sensitivity measures 
were greater among the laboratories than measures of specificity.  Freezing and shipping did not affect 
the results.  It was concluded that a robust and carefully optimised protocol is needed for use of fetal 
DNA testing in routine clinical practice. 
 
More recently, the SAFE NoE organised two workshops in order to assess the consistency of 
performance of NIPD RHD genotyping across laboratories.  The first workshop demonstrated ‘excellent 
reproducibility’ with consistency across 12 laboratories in Europe [72], while the results of the second 
workshop are currently awaited.  Protocols for DNA extraction, as well as sequences for primers and 
probes, were standardised in these workshops.  More work is still needed in this area to establish 
internal laboratory quality control programmes and external quality assurance schemes for NIPD. 
 
A need for external quality assurance (EQA) has also been recognised by the International Society of 
Blood Transfusion (ISBT) and International Council for Standardization in Haematology (ICSH) in the 
general area of molecular blood group genotyping.  Even though this has become routine practice in 
many laboratories around the world, there is little regulation in the form of external quality assurance 
[70].  In order to establish an EQA scheme, an international workshop was organised to identify methods 
used in different laboratories and ascertain accuracy and reliability of these methods.  The 2005 report 
records that two out of six samples, which were distributed among 30 participating laboratories, were 
prepared for RHD genotyping.  A variety of different methods were recorded for RhD testing in these 
laboratories; RHDΨ  was a major cause of error for these samples, as was simple misreporting.  Another 
two samples consisted of plasma from RhD negative pregnant women with plasma from a heterozygous 
RhD positive male added.  Only 15 out of 24 laboratories reported correct results for RHD in these 
samples.  Four laboratories did not obtain conclusive results, while five did not test the samples.  Of the 
15 laboratories that reported correct results, real-time quantitative PCR was used in 11 laboratories; 4 
participants employed conventional PCR.  Different amounts of plasma for DNA extraction and different 
centrifugation steps of the plasma were used.  This international workshop has produced a list of 
recommendations on how to perform molecular blood group genotyping tests and how to present the 
results.  Further workshops will be held every two years. 
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4  CLINICAL VALIDITY 
 
In the papers reviewed, discussion of the future clinical application of NIPD was one of the areas 
generally well covered.  However, papers were less clear when considering the relationship between 
genotype and RhD phenotype, phenotype sensitivity/specificity, and population sampling procedures. 
 
4.1.  RhD genotype/Phenotype Relationship 
 
The general background literature indicates that the relationship between the genotype (the genetic 
makeup) and the phenotype (the RhD status) of individuals depends on the ethnic population to which 
the individual belongs.  Almost all white Caucasian RhD negative individuals lack the RHD gene 
completely, presumably due to 'crossing over' which results in the complete deletion of the RHD gene 
[14].  However, other RhD negative phenotypes can result from a defective, rather than a deleted, RHD 
gene.  Within 8,000 RhD negative blood samples from Europeans, 14 different RHD positive antigen D 
negative and 3 different Del alleles were found.  The cumulative frequency of the first was calculated to 
be 1:1,500 and of the second to be 1:3,000 [2].  Such non-functional genes are more likely to occur in 
certain other population groups e.g. Africans [13].  Several variants have been identified by complex 
serological observations and confirmed and characterised by molecular typing.  Quantitative, as well as 
qualitative, variants have been discovered (Annex 4).  
 
These variants mean that genotyping may not reliably predict the RhD phenotype.  For example, RhD 
variants can result in false RhD positives if the mother carries a non-functional gene which is detected 
by the real-time PCR assay.  In a 2004 feasibility study, fetal RHD genotyping results on maternal 
plasma had to be invalidated in 34 cases out of 893 for this reason [44].  Additional PCRs in exon 4, 
intron 4 and exon 6 were able to identify only 26/34 of the non-functional maternal genes as RHDΨ 
pseudogenes.  Another study did not carry out follow ups of inconclusive results but cited RhD 
polymorphism in general for discrepancies in study results [9]. 
 
The major differences between the RHD and RHCE genes suggest that exon 10 and intron 4 tests 
should provide a suitable testing strategy for the majority of white Caucasians.  A multiplex PCR of these 
two regions would allow a distinction to be made between normal RHD and the clinically most relevant 
partial D category DVI.  This cannot be identified when a duplex exon 7 and exon 10 PCR is carried out 
and, therefore, the result would be noted as inconclusive in these cases [44].  Furthermore, amplification 
of exon 7 will type RHDΨ pseudogenes falsely as RhD positive.  Therefore, testing diverse race 
populations, as opposed to white caucasion populations, requires further adjustments to be made.  It 
has been reported that sequence specific primer pairs for RHD exon 4, RHD exon 5 and RHD exon 6 
could successfully distinguish a RHDΨ from RHD and would correctly type the individual as RhD 
negative [28].  However, information about the ethnic origin of the parents might be helpful since RHDΨ 
or RHD-CE-Ds would give the same result as DVI variants with exons 4, 5 and 10.  This may prove 
difficult in practice.  For example, use of a standard questionnaire to identify ethnic origin proved to have 
low sensitivity/ specificity in a UK trial undertaken to inform policy on the introduction of a national 
haemoglobinopathy screening programme [97]. 
 
A small number of later studies with modifications to allow for D-variants in fetal genotyping in a testing 
strategy were included.  However, it has been suggested that for mass-scale genotyping to be effective 
and for genotyping to replace conventional serotyping of blood, all RHD alleles would need to be fully 
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characterised and, thus, detected [56].  This would be particularly important if NIPD tests were to 
eventually replace postpartum serological blood typing. 
 
4.2.  NIPD Test Phenotype Sensitivity/ Specificity 
 
The papers reviewed did not generally distinguish clearly between phenotypic and genotypic 
sensitivity/specificity when reporting results.  Clinical validity could, therefore, only be addressed by 
looking at the overall test 'accuracy' reported in these studies.  Also, as explained above (section 3.3.2) 
the lack of  reports of sensitivity and specificity rendered many papers of poor quality according to the 
STARD checklist.  Furthermore, alternative reported measures of test diagnostic performance such as 
'detection rate' and 'accuracy' have to be treated with some caution in the papers reviewed, even more 
so since some studies did not include indeterminate results in the calculation of 'accuracy'.  Where 
sensitivity and/or specificity were reported these were sometimes calculated based on a low number of 
samples, for instance 56 RhD-negative pregnant women [88].  Positive and negative predicted values 
were not reported in any of the studies reviewed.   
 
The first clinical report was published by Lo et al. in 1998 [10]. The authors tested 57 pregnant women in 
the UK and reported a ‘detection rate’ of 100% in the second and third trimester but encountered two 
false negatives in the first trimester due to lack of DNA in the sample.  This was the first report to identify 
this new technology as promising for fetal RHD genotyping.  In the following years, several groups 
investigated the performance of this new test.  In 1999, Bischoff et al in the USA detected 70% of 20 
RhD positive fetuses correctly using frozen serum without any false positives [61].  In the same year a 
UK study using reverse transcription of mRNA achieved 75% accuracy [6].  The authors encountered 18 
false positives among 96 RhD negative pregnant women at various stages of gestation and discovered a 
clear trend of increased accuracy with rising gestational age.  Two years later, in 2001, Nelson et al. in 
Australia reported achieving 100% accuracy prospectively in 26 RhD negative women 9-34 weeks 
pregnant with RhD positive fetuses [62]. 
 
Determination of multiple fetal loci from cell free DNA was first described in 2001 by Zhong et al. [47].  
34 second trimester maternal plasma samples were investigated for the RHD and SRY gene.  The 
authors failed to detect the RHD gene in one male fetus.  The following year, Finning et al. [28] reported 
on a study aimed at developing a clinically useful fetal RHD genotyping assay that does not give positive 
results in the case of a RHD gene variant.  The authors combined the sensitivity of real-time PCR with 
an improved RhD typing assay to distinguish RHD from RHDΨ.  This strategy enabled them to correctly 
predict the fetal RHD genotype in 100% of 137 women, 8-42 weeks pregnant.  They utilised exons 4, 5 
and 6 as opposed to exon 7 and 10 which were generally used by other studies.  In the same year 
(2002), the development of a new quantitative real-time PCR enabled Costa et al. [63] to achieve a 
100% detection rate in 102 RhD negative women in the first trimester.  Several further studies with small 
numbers and similar success rates were published in the following years [8, 9, 45, 46, 64, 75, 88] in 
countries like Germany, Norway, Ireland, Denmark, Poland and Switzerland.  These early studies 
reported the promising features of the NIPD test but a number of barriers to uptake into clinical practice 
were also pointed out.  These included: the lack of positive controls for RhD negative female fetuses 
[46]; the considerable number of serological RhD negative individuals with non-functional or rearranged 
RHD genes (4% of RhD negative women) [44]; and the need for larger trials [8]. 
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The first large-scale study was published in 2004 and comprised 893 RhD negative pregnant women 
[44].  This was also the first paper to distinctly mention the inclusion of ‘Asian’ as well as Caucasian 
women in the study.  Using markers for exons 7 and 10 the researchers announced an accuracy rate of 
99.5% with only 5 false positives and 4 false negatives.  However, they also reported that 42 samples 
(5%) had to be excluded due to a non-functional or rearranged RHD gene.  Due to the presence of this 
RHD gene, even though it is not functional, fetuses of women with a variant RHD gene could not be 
RHD genotyped non-invasively. 
 
In 2005, a 2-year-experience study of sensitised women was reported from Belgium.  A total of 223 
fetuses of 218 pregnant women, including 13 Africans and 1 Asian woman, were accurately genotyped 
[87].  A combination of exons 4 and 5 with exon 10 in the testing strategy enabled the group to 
successfully identify fetuses with non-functional RHD genes, of which they encountered four.  As a 
result, non-invasive prenatal determination of fetal RhD has already been introduced into clinical practice 
for sensitised women and has prompted modification of the management of these pregnancies. 
 
Similarly, the provision of a clinical RHD genotyping service for sensitised women in the UK (see section 
2.2.3) was announced in 2004 as a result of a 2002 evaluation study [28].  The objective was to 
effectively reduce invasive procedures by using non-invasive RhD-genotyping.  Up to that point, 283 
sensitised women had been tested and it was reported that the number of invasive procedures could be 
significantly reduced [67].  The test diagnosed the genotype of 223 out of 233 fetuses correctly.  This 
study of sensitised women also identified a further reason for discrepancies between PCR and serology 
results.  In 3 cases, serology showed an RhD-negative genotype while PCR indicated an RhD-positive 
fetus.  It was concluded that serial intrauterine transfusion had possibly led to this discrepancy. 
 
In France in 2005 the use of NIPD tests to more effectively utilise prenatal RhD prophylaxis was 
reported; only patients with an RhD positive fetus were provided with anti-D prophylaxis.  Gautier et al. 
[60] reported that 285 RhD negative, non-sensitised pregnant women of various gestational ages had 
been tested and a 99.3% 'success rate' achieved.  Only two samples could not be tested because these 
were cases of incomplete gene deletions in the mother.  A sensitivity and specificity of 100% was 
reported, based on the 272 patients (96%) who were available for follow up.  
 
In the Czech republic, Hromadnikova et al. [59, 65] have pursued a different aspect of RHD genotyping, 
assessing the feasibility of fetal RHD and RHCE genotyping.  Their 2005 paper reported 100% 
accuracy, but they considered a sample positive if only one of 5 or 7 replicates was positive.  The study 
was restricted to Caucasian pregnant women. 
 
Even though the overall test results look promising and an accuracy rate of 100% has been reported in 
several studies, statements on reported accuracy need to be treated with some caution.  Selective 
participant sampling, variations in the number of replicates taken into consideration for overall test 
results, as well as the exclusion of samples with non-functional or rearranged RHD genes, may have led 
to an overestimation of the reported accuracy rate in several studies [59, 44, 60, 63, 47, 61, 92].  In a 
recent article on design-related bias in studies of diagnostic tests, Lijmer et al. [66] emphasise that 
omitting cases that are difficult to diagnose causes an overestimation of sensitivity and specificity in 
many published papers.  
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4.3  Population Sampling Procedures 
 
Most papers described their population sampling as a consecutive, prospective patient series, although 
a small number of studies did not clearly state how they recruited participants.  Two studies recruited 
their study population retrospectively.  The characteristics of the populations recruited varied quite 
considerably between studies and sampling did not always guard against bias.  Some smaller studies 
even carried out selective participant sampling by choosing their participants against pre-specified 
criteria.  One study selected 24 negative pregnant women and 4 patients with weak D phenotypes as the 
study population [58].  This implies an anticipation of identifying the four D variants.  Other studies 
recruited women who were about to undergo invasive procedures [6, 47] or were about to receive 
genetic counselling [63].  This indicates that these studies concentrated on at risk pregnancies, which 
may not resemble the general pregnant population.  Some studies concentrated on sensitised women 
[67], while others tested only non-alloimmunised pregnant women [60].  Selective participant sampling 
was taken even further by Nelson et al. [62], who recruited only RhD-negative pregnant women with 
RhD-positive fetuses and Bischoff et al. [61], who used retrospectively frozen serum of sensitised RhD 
negative women with RhD-positive fetuses.  The ability of these studies to address clinical validity and 
test accuracy in the general population has to be questioned. 
 
Restriction of patient sampling to Caucasians also reduces the clinical validity of findings, as does failure 
to report the make-up of the study population.  Both were observed in the papers reviewed.  In fact, most 
studies included in this report did not state the ethnic background of the sample population.  Three 
studies specified their study population as Caucasian only [59, 60, 65], while only two studies described 
their study population in more detail.  One study population was simply defined as a mixed population of 
Caucasians and Asians [44].  In this study, both sensitised and non-sensitised RhD negative pregnant 
women were tested.  The other reported the inclusion of 13 Africans in the study population, of which 3 
were of North African origin, and one Asian woman [87].  Although the study populations in this study 
probably reflects the likely testing clientele in Europe, numbers are too small to allow generalisation.  
 
Three studies [11, 28, 67] may have included mixed populations because they reported random 
participant sampling.  Finning et al. [28, 67] specifically adapted primer combinations in order to allow 
differentiation between various D variants including those prominent in people of African origin (see 
Annex 4).  The negative phenotype in Blacks is more commonly caused by an RHD pseudogene 
(RHDΨ) or a hybrid gene (RHD-CE-DS).  Overall, 67% of RhD negative black individuals have the 
pseudogene and 15% the hybrid gene.  In African-Americans, the corresponding figures are 24% and 
22% [54].  NIPD test diagnostic accuracy in US ethnic minorities (e.g. African Americans) has not been 
reported in any published studies. 
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5 SOCIO-ECONOMIC IMPLICATIONS 
 
5.1  RhD NIPD Economic Evaluations 
 
Economic evaluation of NIPD tests used in the context of RAADP for RhD negative pregnancies has 
been initiated in the Netherlands [11].  In their 2005 (unpublished) report, three scenarios are 
considered: 1) Current RAADP policy (i.e. only pregnant women with no living child, about 16,000, 
receive prenatal prophylaxis); 2) NIPD (PCR-test) employed to target RAADP in nulliparous women only; 
3) NIPD PCR-test employed in all nulliparous and multiparous women.  In a cost analysis, it was 
concluded, based on the Dutch model: that scenario 2) is 4.5% less expensive than current RAADP 
practice in the Netherlands; and that scenario 3) is 11.5% more expensive than current practice.  There 
are no full economic evaluations e.g. including cost-utility measures.  Further evidence on cost-
effectiveness is required if wider implementation of RAADP plus RhD NIPD is to be supported by policy 
makers and health insurers.  There are similarly no published economic evaluations of NIPD use in 
sensitised pregnancies. 
 
In contrast, a cost-effectiveness analysis of the introduction of RAADP for pregnant women who are 
rhesus-negative is presented by Chilcott et al. in a UK report published in 2003 [1].  The authors 
concluded that RAADP could provide a cost-effective intervention when prevention of haemolytic 
disease of the newborn is taken into account.  The report estimated that RAADP (2 doses) given to all 
pregnant women who are RhD-negative would be economically attractive, using a maximum acceptable 
cost-utility ratio of £30,000 per quality adjusted life year (QALY) as indicated by NICE [1].  Furthermore, 
because NHS list price (2002) for anti-D was used in these calculations, the authors suggested that in 
clinical practice, due to price variability, cost-effectiveness might be even better. 
 
The ongoing work of the SAFE Socio-economic group includes co-ordinated economic modelling of RhD 
NIPD introduction into five selected countries (UK, France, Germany, the Netherlands and India).  
 
5.2  RhD NIPD Technology Implementation 
 
The first large scale clinical trial with automated high throughput screening of RhD negative women, to 
prove the suitability of the technology for mass screening, was also carried out in the Netherlands [11]. 
Using only the exon 7 PCR assay, a diagnostic 'accuracy' of 99.4% was reported with ‘equivalent’ test 
performance in all ethnic groups.  Test accuracy in the specialist centre was reported to be higher than 
the serological test in a multi-centre routine setting. 
 
This study is important since it shows development and progress from diagnostic evaluation studies to 
implementation in a clinical context.  The report also provides a picture of how test delivery might best fit 
into current prenatal care in order for it to be cost-effective.  The Dutch study reveals that only 
centralised implementation (i.e. 1-2 labs nationally) would be economically justified and the authors also 
suggest combining the time of testing with the 30th week antibody screening to reduce costs.  
 
Further improvements in test performance for diverse populations can be expected after a PCR assay 
multiplexing exon 7 PCR with exon 5 has been validated by the same group.  This assay will enable the 
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provision of results for women with an RHD pseudogene and the RHD variant type VI in the testing 
population.  These are the most common variant genes in Africans and Caucasians, respectively.  The 
improved test will result in a negative PCR in both cases and will not produce false positives.  
 
Centres in Bristol, UK, Göttingen, Germany and Paris and Marseilles, France have started to offer RhD 
NIPD tests in clinical practice (by request) for non-sensitised as well as sensitised women.  However, no 
publications on the former have been produced to date. 
 
5.3 Risks and Limitations of Current NIPD Technology 
 
The major risk associated with the introduction of RhD NIPD technology relates to the accuracy of the 
test in a mixed population.  While a number of 2004 and 2005 publications indicate 99-100% accuracy 
rates [44, 58, 60], the true accuracy rate at the population level might be lower.  The large number of 
variations in the RHD gene makes it difficult for primers to detect 100% of RhD variants using currently 
available technologies.  As of now, a small percentage of misdiagnoses are unavoidable.  The main 
disadvantage is linked to false negatives, with the associated risk that a small number of women may 
not receive prenatal anti-D, even though the fetal-maternal gene set-up would require it.  Thus, unless 
100% sensitivity (ability of test to detect RhD positive fetus when present) can be achieved these women 
might become sensitised with a likelihood of <2%  [16], thereby increasing the total number of sensitised 
cases in a country.  Furthermore, until 100% sensitivity and specificity (ability of test to exclude RhD 
positive fetus) rates are achieved, the post-birth blood cord sampling procedure is unlikely to be avoided 
even if the woman’s fetus has been tested prenatally.  The ability to abandon blood cord sampling would 
be an important factor influencing cost-effectiveness in favour of RhD NIPD implementation. 
 
In terms of limitations, studies identify that at present testing women in the second trimester increases 
accuracy rates.   Thus, the optimum time (as of now) for RhD NIPD testing is around week 26.  This may 
require an additional appointment for a woman in different healthcare systems.  However, it is 
anticipated that when further markers are developed, testing could be moved to earlier in the pregnancy 
and possibly be combined with other tests during the first prenatal appointment. 
 
A further limitation of the RhD NIPD technology is that it requires specialist skills and laboratory 
infrastructure in order to conduct population level testing.  While the necessary technology exists, the 
organisation of laboratory services, provision of high-throughput equipment, development of internal 
laboratory QA measures and an external quality assurance (EQA) scheme, and the training of laboratory 
personnel, physicians, midwives and nurses will require significant financial investment.  
 
Finally, a potential unintended consequence of NIPD test development generally was highlighted in 2005 
with articles reporting a home-based prenatal fetal gender test being offered by an online pregnancy 
store [77, 78].  The Baby Gender Mentor test involves self-collection of blood spot samples that are 
shipped directly to the manufacturer’s laboratory for rapid turn-around.  The manufacturers claimed the 
test could be used as early as 5 weeks into pregnancy and reported >99.9% accuracy [79].  The caution 
expressed by a number of scientists about the quoted test performance appears to be justified as wrong 
diagnoses have been revealed [80].  These have led to a class-action lawsuit being filed against the 
manufacturer (further information see www.in-gender.com).  Non-invasive prenatal tests are also being 
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developed for the establishment of paternity during the term of pregnancy, with non-invasive paternity 
testing being offered throughout the world [81]. 
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6  ONGOING RESEARCH 
 
Further research is currently ongoing in all areas concerned with RhD NIPD test accuracy and reliability, 
as well as the development of large scale clinical trials. 
 
A Scottish project was launched in 2002 to contribute to the general investigation of the feasibility of 
RHD fetal genotyping [98].  The aim was to test 100 primigravidae women and record reductions in 
diagnostic amniocentesis.  This study is still ongoing.  In 2004, the same group reported results of their 
ongoing development of the real-time PCR assay, in which they target exons 4, 5 and 7 of the RHD 
gene [92].  They have also expanded the field of application to the KELL blood group [93].  
 
In terms of test development, standardisation of real-time PCR, the development of suitable positive 
controls for RhD negative female DNA samples, and alternative DNA sampling methods (i.e. 
transcervical canal aspirates) addressed in England [94].  There are also reports to indicate that MLPA 
(multiplex ligation-dependent probe amplification) may become a cost-effective alternative to real-time 
PCR.  Although this technique lacks the sensitivity of real-time PCR, it possesses greater specificity due 
to the ability to test for a great number of markers simultaneously.  A comprehensive RHD diagnostic 
MLPA test has been reported that includes probes for 7 out of the 10 RHD exons.  Markers were 
selected to enable the test to identify several RhD polymorphisms.  This new approach appears very 
promising since the combination of MLPA with real-time PCR (in the form of the novel LigAmp 
technique) would combine the sensitivity of one technology with the specificity of the other [94]. 
 
Confirmation of the technical performance of the RhD NIPD test method in prospective trials in mixed 
populations is still outstanding.  In England, the IBGRL has set out to address this gap in the evidence.  
A trial will be mounted, adhering to the STARD checklist, to include 5,000 samples starting in 2006 [67].  
Spare blood samples from women at about 28 weeks gestation will be made available from 5 antenatal 
laboratories in the UK.  The samples will be tested for exon 5 and 7 in order to include RHDΨ detection.  
 
Finally, a recent (unpublished) poster has presented the first meta-analysis of studies reporting the 
accuracy of non-invasive fetal RHD genotyping from maternal blood [95].  In their analysis the authors 
used a random effect model to compare results obtained from a number of studies with a total of 3,078 
samples.  A composite sensitivity of 0.954, specificity of 0.986, positive predictive value (PPV) of 0.990 
and negative predictive value (NPV) of 0.921 were reported.  Studies appear not to have been assessed 
for quality against the STARD or other checklist. 
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7 GAPS IN THE LITERATURE 
 
At present a number of gaps exist in the literature on the given topic since the technology is new.  As far 
as the fundamental science is concerned, it may take a few more years before the answers to some of 
these questions are available.  On the other hand, the RhD NIPD technology is moving quickly towards 
the phase of clinical trials and we expect to see reports on test performance in large populations and 
different ethnic groups in the near future. 
 
Evidence on test accuracy 
Currently, the majority of reports on RhD NIPD performance are based on a small number of samples 
(N<100), with only the Dutch study based on a very large sample population of 2,543 women [11].  
There is also a need to assess the performance of the technology in a diverse population in order to be 
able to evaluate the likely sensitivity and specificity of the test at a population level.  Studies to date have 
included relatively small numbers of ethnic minority participants. 
 
As can be seen in Appendix 2, application of the STARD checklist to currently published scientific 
papers leads to the conclusion that most studies of diagnostic accuracy are of poor design and quality.  
For more thorough evaluation of NIPD tests, we need studies which not only investigate a greater 
number of women but also report on clinical genotypic and phenotypic sensitivity/specificity, as well as 
specifying the statistical certainty and uncertainty of any results obtained.  Furthermore, elimination of 
any potential bias due to sampling of participants and a generally more rigorous approach towards the 
study design is desirable, including blinding of test readers, recording of time and place of recruitment, 
and inclusion of 'booster' samples for black and ethnic minority groups if necessary. 
 
Evidence on quality assurance 
An optimum testing protocol (test standardisation) in conjunction with internal laboratory QA measures 
needs to be finalised.  External quality assurance (EQA) schemes also need to be developed for RhD 
NIPD.  As part of this process, further comparisons of results in multiple laboratories would be valuable, 
as well as reports of the skill levels required for implementation of the new test. 
 
Guidelines on the management of RhD negative pregnancies differ from country to country and, for the 
most part, these are not published in international literature.  Information is needed on current 
management of these pregnancies; incidence of sensitisation and HDN, and laboratory expertise and 
organisation. 
 
Broader socio-economic implications 
As Section 5 makes clear, there are very few studies covering the broader socio-economic aspects of 
the new technology and the medical condition concerned.  Further studies of cost-effectiveness and 
economic modelling in different countries are essential.  An international overview of practices in 
prenatal care, costs, types of healthcare system and usage of non-invasive technologies would be an 
invaluable document in this respect.  Also, even though the risks and ethical issues associated with the 
introduction of NIPD RhD tests into clinical practice may be viewed as of lower priority than for other 
genetic tests, they cannot be ignored.  From the risk perspective, issues associated with the sensitivity 
and specificity of the test need to be communicated to women, as do possible (even though unlikely) 
side effects from the use of anti-D products (serum or recombinant).  From the ethical perspective, 
issues of population diversity and women’s choice will become relevant as the test enters the population 
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level of adoption.  Furthermore, the potential use of the new technology for fetal gender identification 
and, therefore, possible sex selection, should not be ignored. 
 
The available evidence on risk communication to pregnant women and informed choice are being 
examined by two other SAFE workpackages (WP5 on Psychosocial aspects of risk communication and 
WP7 on Ethical aspects).  Their activity will hopefully provide some information concerning risks and 
ethical aspects relevant to NIPD for RHD genotyping.  At present, this technology has not been 
evaluated from either the risk or ethics perspective in the literature. 
 
Finally, in terms of organisational implications, no publications exist which describe the necessary 
arrangements, i.e. infrastructure and finance in order to fully automate procedures, create universal kits 
for RhD NIPD and set up central laboratories.  The factors which will influence market entry need to be 
researched.   
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8  CONCLUSIONS 
 
It is evident from this literature review that NIPD RhD tests have entered, or are about to enter, clinical 
practice in a number of countries.  The evidence base remains, at present, incomplete in many respects. 
 
For sensitised women, it is recognised that the current use of prenatal invasive technologies is 
associated with an increased risk of miscarriage.  Prenatal diagnostics for these women would therefore 
benefit from a move away from the use of invasive tests towards the use of non-invasive techniques.  
Non-invasive fetal RHD genotype testing is already being used in combination with other tests for the 
care of sensitised women in the UK, Czech Republic, the Netherlands, and some other countries.  This 
can be interpreted as a successful introduction of NIPD tests into prenatal care.  However, NIPD tests 
are currently more consistently accurate in the 2nd trimester (around week 26).  Non-invasive testing 
during the first trimester would alleviate worry and remove procedures in pregnancies where the fetus is 
found to be RhD negative.  Studies to further develop the test have been undertaken in laboratories in 
the UK, the Netherlands, Belgium, France, Italy, Hong Kong and the USA. 
Since 2005, trials have also been underway of non-invasive diagnosis of fetal RHD genotype in routine 
pregnancies of RhD negative women - a much larger group of women.  For non-sensitised women, the 
use of NIPD to target routine antenatal anti-D prophylaxis is more complex.  At present, conclusions 
cannot be drawn purely from the peer reviewed literature covering non-invasive prenatal RHD 
genotyping.  Additional information is needed to reveal the present state of development of the NIPD 
technology.  Overall, the technology continues to be in the experimental stage rather than clinical 
practice.  Efforts to collect more data from large scale population studies continue and the number of 
tests performed is increasing rapidly.  It is clear that introduction of NIPD testing at a national level will 
require the establishment of centralised, automated laboratories, additional training for physicians, 
midwives and laboratory technicians, as well as information dissemination to patients in each country.  
To what extent and at what cost has not been quantified at the present date. 
 
Taking this into consideration, there is no clear evidence as yet to demonstrate whether this new 
technology will be significantly more cost-effective than current practice for non-sensitised pregnancies.  
Further cost-effectiveness studies, building on the Netherlands study, which include all known cost 
factors, are urgently required and should include an attempt to identify currently unknown costs.  This is 
the aim of the SAFE NoE (WP6  on Socio-economics) and work on economic modelling has already 
commenced.  To date, the introduction of RhD NIPD has not occurred on grounds of cost-effectiveness 
and the future development will be followed with great interest. 
 
Aside from the issue of direct costs, there may be other opportunity costs associated with different 
approaches.  The use of donor blood for the production of anti-D immunoglobulin, for example, could be 
reduced by approximately 40% or less and used for other products or purposes, if RhD NIPD tests were 
introduced. 
  
However, while the introduction of RhD NIPD tests will help to identify the need for routine antenatal 
anti-D prophylaxis (RAADP), overall this test is unlikely to significantly decrease the total number of 
sensitisations and cases of HDN compared to the impact achieved by a universal RAADP.  
 
Furthermore, despite the reported benefits of RAADP in decreasing the number of sensitisations and 
cases of HDN further than postnatal prophylaxis alone, only postnatal administration of anti-D is 
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practised in many countries.  The development of RhD NIPD tests may have the potential to influence 
the implementation of RAADP in these countries, if cost-effectiveness can be demonstrated.  In other 
countries like the UK where policy guidelines exist for RAADP, but are not uniformly followed, NIPD may 
improve uptake.  
 
Finally, it might be argued that the clinical benefits are too insignificant for RhD NIPD to be introduced 
into the routine prenatal care of non-sensitised women.  However, successful introduction of these tests 
may be advantageous in allowing other NIPD tests, based on similar techniques, to be incorporated into 
the system of prenatal diagnostics in countries.  Thus the RhD test may have a role as a pioneering 
technology in the area of NIPD testing and could help to establish techniques and quality assurance 
mechanisms, and set up laboratories and required infrastructure, thus generating a platform from which 
implementation of other NIPD tests can easily take off.  A goal for the future might be one sample for a 
series of NIPD analyses carried out in the first trimester of pregancy.  RhD NIPD would then be just one 
component in an overall test package that could help to determine pregnancy status, future fetal 
development and likely pregnancy outcome.  In this context, RhD NIPD implementation can be viewed 
as essential to kick-start the introduction of NIPD technology more broadly.  
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Annex 1:  STARD checklist for reporting NIPD study diagnostic accuracy 
 
 
 
Section and topic No Checklist items Yes/ No 
TITLE/ABSTRACT/ 
KEYWORDS 
1 Identify the article as a study on diagnostic accuracy (recommend MeSH heading 
'sensitivity and specificity'). 
 
 
INTRODUCTION  2 State the research questions or study aims, such as estimating diagnostic accuracy 
or comparing accuracy between tests or across participant groups. 
 
METHODS    
Participants 3 Describe the study population: The inclusion and exclusion criteria, setting and 
locations where the data were collected. 
 
 4 Describe participant recruitment: Was recruitment based on presenting symptoms, 
results from previous tests, or the fact that the participants had received the index 
tests or the reference standard? 
 
 5 Describe participant sampling: Was the study population a consecutive series of 
participants defined by selection criteria in items 3 and 4? If not, specify how 
participants were further selected. 
 
 6 Describe data collection: Was data collection planned before the index test and 
reference standard were performed (prospective study) or after (retrospective study)? 
 
Test method 7 Describe the reference standard and its rationale  
 8 Describe technical specification of material and methods involved including how and 
when measurements were taken, and/or cite references for index tests and reference 
standard. 
 
 9 Describe definition and rationale for the units, cutoffs and/or categories of the results 
of the index test(s) and the reference standard. 
 
 10 Describe the number, training and expertise of the persons executing and reading 
the index tests and the reference standard. 
 
 11 Describe whether or not the readers of the index tests and reference standard were 
blind (masked) to the results of the other test and describe any other clinical 
information available to the readers. 
 
Statistical methods 12 Describe methods for calculating or comparing measures of diagnostic accuracy, and 
the statistical methods used to quantify uncertainty (e.g. 95% confidence intervals). 
 
 13 Describe methods for calculating test reproducibility, if done.  
 
RESULTS    
Participants 14 Report when study was done, including beginning and ending dates of recruitment.  
 
 15 Report clinical and demographic characteristics of the study population  (e.g. age, 
sex, spectrum of presenting symptoms, comorbidity, current treatments, recruitment 
centers). 
 
 16 Report the number of participants satisfying the criteria for inclusion that did or did 
not undergo the index tests and/or the reference standard; describe why participants 
failed to receive either test (a flow diagram is strongly recommended). 
 
Test results 17 Report time interval from the index tests to the reference standard, and any treatment 
administered between. 
 
 18 Report distribution of severity of disease (define criteria) in those with the target 
condition; other diagnoses in participants without the target condition. 
 
 19 Report a cross tabulation of the results of the index tests (including indeterminate and 
missing results) by the results of the reference standard; for continuous results, the 
distribution of the test results by the results of the reference standard. 
 
 20 Report any adverse events of index tests and reference standard  
 
 21 Report estimates of diagnostic accuracy and measures of statistical certainty (e.g. 
95% confidence intervals). 
 
 22 Report how indeterminate results, missing responses and outliers of index tests were 
handled. 
 
 23 Report estimates of variability of diagnostic accuracy between subgroups of 
participants, readers or centers, if done. 
 
 24 Report estimates  of test reproducibility, if done  
 
DISCUSSION    
Discussion 25 Discuss the clinical applicability of the study findings  
 
 
 
A Review of Evidence on Non-invasive Prenatal Diagnosis (NIPD):                                                                                                                                                                                                           Annex 2                             
Tests for Fetal RHD Genotype 
 
Annex 2: Overview of scientific papers reviewed 
Literature Summary of scientific papers: technical evaluation of NIPD RhD 
Year and 
country 
Study 
Type Study aim Title 
Method / Ref 
test 
Foetal cells 
(FC) / free 
foetal DNA 
(ffDNA) 
Exons / Introns 
tested Replicates 
Sample no 
/gestation Sensitivity/Specificity Outcome 
Author and 
Publication Score * 
Netherla
nds 
2005 
(ZonMw) 
Prosp
ective 
Enhance the efficiency 
of immunoprophylaxis 
in RhD- pregnancies 
by selective, PCR-
guided, prenatal 
administration rather 
than universal 
administration of anti 
D-IgG 
Prenatal foetal RhD 
blood group typing to 
enhance efficiency 
of prenatal anti-D 
immunoprophylaxis 
in RHD negative 
pregnant women 
Real time 
PCR / 
serology 
 
Exon 7, 
additionally 
exon 5 if RhD 
variant is 
suspected 
3 replicates, 
only samples 
with 2 or 3 
positive wells 
were scored 
as a positive 
test 
Random cohort of 
2500 (2380) blood 
samples of RhD-
negative 30th 
week pregnant 
women sent in for 
allo-antibody 
screening (Sept -
Dec 2003) 
5 false positives, 3 false 
negatives, 99.4% 
accuracy 
Diagnostic accuracy was 99.4%, test 
performed well in all ethnic groups. A 
small economic benefit is achieved. 
No disadvantages were observed; 
only centralised implementation 
(including registration, surveillance, 
and PCR adaptation) is economically 
efficient. 
Bonsel, H.  et  al. 
ZonMw 
No peer-reviewed 
report 
Denmar
k 
2005 
Prosp
ective 
To establish a reliable 
test for prenatal 
prediction of foetal 
RhD type 
Reliable test for 
prenatal prediction of 
foetal RhD type 
using maternal 
plasma from RhD 
negative women 
Novel real 
time PCR-
based exon 
7 assay 
combined 
with exon 10 
assay / 
serology 
ffDNA from 
plasma 
Exons 7 and 
10 4 replicates 
56 RhD negative 
pregnant women 
15-36 weeks 
pregnant including 
18 stored samples 
from UK for final 
validation of assay 
Specificity: 94.7% 
Sensitivity: 100%         
100% concordance 
from 16th week, one 
sample from 15th week 
was inconclusive, 
sample was considered 
positive when at least 
two replicates were 
positive for both exons 
Set up was very reliable 
Clausen, F.B. et  
al. Prenatal Diagn 
(in press) 
9.5/25 
Belgium 
2005 
in 
Frenc
h 
To evaluate the 
predictive value of 
RhD foetal genotyping 
Prenatal 
determination of 
foetal RHD in 
maternal plasma: 
two-years 
experience of routine 
clinical use 
Real-time 
multiplex 
PCR / 
serology 
ffDNA from 
plasma 
Exons 4, 5, 
and 10  
218 pregnant 
women of various 
gestational ages 
including 5 twin 
pregnancies 
100% concordance, 3 
positive cases for exon 
10 due to RhD psi in 
mother 
Using this method for two years in 
routine practice has led us to modify 
out management scheme for 
sensitised RhD negative pregnant 
women 
Minon, J.-M. et  al. 
J Gynecol Obstet 
Biol Reprod 
34:448-453 
11/25 
Czech 
Republi
c 
2005 
Prosp
ective  
Non-invasive foetal 
RHD and RHCE 
genotyping from 
maternal plasma in 
alloimmunised 
pregnancies 
Real time 
PCR / 
serology 
ffDNA from 
plasma 
RHD: exons 7 
and 10 RHCE: 
intron 2 and 
exon 5 
7 replicates 
23 alloimmunised 
Caucasian 
pregnant women 
(16 anti-D; 5 anti-
D+C; 2 anti E) 11 
to 37 weeks 
pregnant 
100% (in three samples 
foetal DNA very low. 2 
cases developed severe 
HDN) 
Present data present compelling 
argument that this type of testing may 
be incorporated into our clinical 
diagnostic algorithm for following 
pregnancies at risk for HDN. 
Hromadnikova, I. et 
al.  Prenatal 
Diagnosis 25(12): 
1079-1083 
10.5/25 
Czech 
Republi
c 
2005 
Prosp
ective 
Assess feasibility of 
foetal RHD and RHCE 
genotyping 
Non-invasive Foetal 
RhD and RhCE 
Genotyping using 
real-time PCR 
testing of maternal 
plasma in RhD 
negative 
pregnancies 
Real time 
PCR / 
serology 
ffDNA from 
plasma 
RHD: exons 7 
and 10 RHCE: 
exon 2  and 5 
5 replicates 
45 RhD negative 
Caucasian 
pregnant women 
11to 40 weeks 
pregnant 
100% accuracy rate 
sample was considered 
positive if at least one 
replicate was positive 
Non-invasive RhD is recommended 
together with foetal sex determination 
in alloimmunised D-negative 
pregnancies 
Hromadnikova, I. et 
al.  Journal of 
Histochemistry and 
Cytochemistry 
53(3): 301-5 
11/25 
Czech 
Republi
c 
2005 
Prosp
ective  
Non-invasive foetal 
RhD exon 7 and 
exon 10 genotyping 
using real-time PCR 
testing of foetal DNA 
in maternal plasma 
Real time 
PCR / 
serology 
ffDNA from 
plasma 
Exons 7 and 
10 5 replicates 
24 RhD-negative 
pregnant women 
and 4 patients with 
weak D 
phenotypes, 11 to 
38 weeks pregnant 
(mainly II and III  
trimester) 
Specificity approaching 
100%; sensitivity 100% 
for exon 7; 2 exon 10 
not detected despite 
positive exon 7 results 
(1 could be shown to be 
absent) 
Non-invasive prenatal RhD 
genotyping should involve the 
amplification of at least two RhD-
specific products. 
Hromadnikova, I. et 
al.  Foetal Diagn 
Ther 20(4): 275-
280 
9.5/25 
Spain 
2005 
Prosp
ective 
Evaluate the use of 
foetal DNA in maternal 
plasma for clinical 
application 
Application of foetal 
DNA detection in 
maternal plasma: a 
prenatal diagnosis 
unit experience 
Real-time 
multiplex 
PCR / PCR 
from CVS or 
amniotic fluid 
ffDNA from 
plasma Exon 7  
20 RhD negative 
pregnant women 
11 to 16 weeks 
pregnant 
90% sensitivity 
Successful application of QF-PCR to 
diagnose Huntington disease and 
cystic fibrosis, 90% for foetal RhD 
were correctly diagnosed. Foetal RhD 
status detection has been considered 
a useful tool in cases of sensitised 
women with heterozygous partners. 
An assay with a larger number of 
patients is being performed to 
determine sensitivity and usefulness. 
DNA samples should be processed as 
quickly as possible. 
Gonzalez-
Gonzalez,C. et  al.    
J. Histochem 
Cytomchem 53 (3): 
307-14 
4.5/25 
* Assessment against STARD checklist by a second independent reviewer is still required
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France 
2005 
Prosp
ective  
Foetal RhD 
genotyping by 
maternal serum 
analysis: a two year 
experience 
Real-time 
PCR / PCR 
from 
amniotic 
cells or 
serology 
ffDNA from 
serum exon 10 4 replicates 
285 RhD negative 
pregnant women 
(Caucasians, non 
sensitised), 8-35 
weeks pregnant  
In 2 cases RhD status 
could not be determined 
due to uncomplete RHD 
gene deletion in mother 
(gene variant) 100% 
accuracy in 272 patients 
that were available for 
follow up specificity and 
sensitivity of the assay 
were 100% overall 
success rate 99.3% 
Prophylaxis was not provided to 
patients with RhD negative fetus. 
RhD genotyping assay can be 
systematically proposed to all RhD-
negative women in order to more 
effectively utilize RhD prophylaxis. 
Gautier, E. and Costa, 
J-M. et  al. American 
Journal of Obstetrics 
and Gynaecology 
192: 666-9 
15/25 
Netherla
nds 
2004 
Abstr
act  
Screening for foetal 
RHD-genotype by 
plasma PCR in all D-
negative pregnant 
women is feasible 
Real-time 
exon 7 PCR / 
serology 
ffDNA from 
plasma   
2543 D-negative 
pregnant women, 
28-30 weeks 
pregnant 
Specificity: 98.2% 
sensitivity: 98.2% in 7 
cases genotype 
suggests D-positivity 
maybe due to weak-D 
or null alleles. In 7 
cases no RHD-
sequence were 
detected but cord blood 
was typed positive. 
First large scale study 
demonstrating the feasibility of 
screening D-negative women to 
restrict prenatal anti-D to women 
carrying D-positive fetuses. Using 
an automated assay. 
Van der Schoot, C.E. 
et  al.        Vox Sang 
87 (Suppl3): Abstract 
(Tu07.04) 
Short abstract 
UK 
2004 
Prosp
ective  
A clinical service in 
the UK to predict 
foetal Rh (Rhesus) D 
blood group using 
free foetal DNA in 
maternal plasma 
Real time 
multiplex 
PCR / 
serology 
ffDNA from 
plasma 
Exons 4,5 
(excluding 
RhD (psi)) and 
10 
4 replicates 
283 immunised 
pregnant women 
with heterozygous 
partner 
50 confirmatory results 
awaited, 223 correctly 
predicted, no result in 7 
cases, 3 cases with 
discrepant serology 
(possibly due to 
intrauterine 
transfusions) 
Providing the non-invasive test for 
foetal genotyping has significantly 
reduced the number of invasive 
procedures carried out in the UK. 
Future application: to reduce anti-D 
application (currently 10500 RhD 
negative pregnant women per year 
in England and Wales) 
Finning, K. et  al.        
Ann N Y Acad Sci 
1022: 119-123 
5.5/25 
UK 
2004 
2 
case 
studie
s 
 
Use of maternal 
plasma for non-
invasive 
determination of 
foetal RhD status 
PCR / 
amniocentesi
s / serology 
in case two 
ffDNA of 
plasma   
2 samples from 
RhD Sensitized 
patients 18 weeks 
pregnant 
Both cases RhD status 
accurately determined 
Maternal plasma testing for foetal 
RhD status represents a new tool 
in the management of  cases of 
RhD sensitisation in pregnancy. 
RhD negative girl in first case 
prompted amniocentesis in week 
20. 
Harper, T.C. 
American J. of Obstet 
& Gyn 191: 1730-2 
Case study 
France 
2004 
Prosp
ective 
Feasibility and 
accuracy of large 
scale RhD foetal 
diagnosis in RhD 
negative women and 
to validate the 
diagnostic use of 
foetal RHD genotyping 
Large-scale pre-
diagnosis study of 
foetal RHD 
genotyping by PCR 
on plasma DNA from 
RhD-negative 
pregnant women 
Conventional 
and real time 
PCR / PCR 
from 
amniotic 
cells  or 
serology 
ffDNA from 
plasma 
Exons 7 and 
10 
2 replicates 
(one 
conventional 
PCR one real 
time PCR), 
positive 
result if at 
least exon 7 
was positive 
in both PCRs 
893 RhD-negative 
women 
(Caucasians and 
Asians) immunised 
and non-
immunised 7 to 40 
weeks pregnant 
42 samples were 
excluded due to non-
functional or rearranged 
RHD gene (4% of RhD 
negative women); 
accuracy  99.5%, 5 
false positives, 4 false 
negatives 
Exons 7 and 10 of RhD gene were 
amplified. A strategy is proposed to 
avoid small number of false 
positives and negatives. Real time 
PCR is not more sensitive than 
conventional PCR but has an extra 
level of protection against 
contamination, less time 
consuming, best specificity 
Rouillac-Le Sciellour, 
C. et  al.         Mol 
Diagn. 8(1): 23-31 
11/25 
Poland 
2004 
prosp
ective 
Detection of fetal RHD 
gene in the plasma of 
RhD negative mother 
and comparison with 
RhD of the newborn 
Non-invasive foetal 
RhD typing and RhD 
negative pregnant 
women - prelim. 
Observations 
Real-time 
PCR 
ff DNA 
from 
plasma 
Exons 7 and 
10  
45 plasma 
samples of 28 RhD 
negative women, 
various gestation 
age 
All 23 RhD positive 
fetuses were detected, 
in 5 RhD negative 
samples other fetal 
genes were detected 
Real-time PCR is an appropriate 
non-invasive method for foetal RhD 
examination, 2 RhD exons should 
be examined 
Guz, K. et  al.  
Ginekol Pol 75: 21-5 Polish 
Ireland 
2003 
Prosp
ective  
Detection of foetal 
Rhesus D gene in a 
whole blood of 
women booking for 
routine prenatal care 
Real time 
quantitative 
PCR / 
serology 
ffDNA from 
whole 
blood 
Exon 10  
31RhD negative 
women            
before 20 weeks 
gestation 
82% accuracy rate no 
false positives 
Whole blood used, larger volume of 
blood for DNA extraction increased 
sensitivity of RhD assay, non-
invasive procedure is feasible, 
more studies needed. Real time 
quantitative PCR can be used for 
RhD genotyping of fetus if false 
negative results can be eliminated. 
18% of RhD+ babies would not be 
detected at the first prenatal visit. 
Foetal DNA analysis was not 
revealed until after delivery. 
Turner, M.J. et  al. 
European J. of 
Obstetrics and 
Gynaecology and 
Reproductive Biology 
108: 29-32 
13/25 
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Australi
a 
2003 
Prosp
ective 
/ 
retros
pectiv
e 
 
Evaluation of the 
clinical usefulness of 
isolation of foetal 
DNA from the 
maternal circulation 
PCR / 
serology 
ffDNA from 
plasma or 
serum 
Exons 7 and 
10  
28 blood samples 
of RHD-negative 
women 15-17 
weeks pregnant 
collected for 
maternal triple 
serum screening 
3 false negative  and 2 
false positive results 
Both amplifications of the Rh genes 
were performed in the same tube. It 
is necessary to safeguard against 
contamination and cover the 
polymorphisms present within the 
RhD gene. False positives may 
result from gene rearrangements 
and false negatives due to non-
functioning genes. Out of 24 
samples 21 were correctly sexed. 
Siva, S.C. et al.         
Aust N Z J Obstet 
Gynaecol 43(1): 10-
15 
12.5/25 
Norway 
2003 
Prosp
ective 
Performing foetal RhD 
genotyping 
investigating the effect 
of storage temp on 
DNA concentration 
Prenatal genotyping 
of RHD and SRY 
using maternal blood 
Monoplex 
and duplex 
fluorescent 
PCR / 
serology 
ffDNA from 
blood Exon 7 
2 – 5 
replicates 
114 RhD negative 
women 6-38 
weeks pregnant 22 
samples in duplex 
with SRY gene 
290 samples: 32 false 
negatives, 4 false 
positives discrepancy: 
12%, 8% if one positive 
replicate counts as 
positive result 
There was a statistically significant 
reduction of foetal DNA in samples 
stored at room temperature. Duplex 
PCR showed reduced sensitivity for 
SRY gene amplification. Lack of 
positive control for RHD negative 
female fetuses. Therefore this 
duplex PCR is not suitable for 
routine analysis. 
Randen, I. Et al.        
Vox Sanguinis 85: 
300-306 
9.5/25 
Australi
a 
2003 
Prosp
ective 
letter 
 
Variation in the 
reliability of RHD 
prenatal genotyping 
using the 
polymerase chain 
reaction and 
targeting multiple 
exons of the RHD 
gene 
Conventional 
PCR / 
serology 
ffDNA from 
plasma 
Exons 7 and 
10  
47 RhD negative 
pregnant women 
(II and III) 
Exon         4     5   10 
Sensitivity 62   50   94 
Specificity 91 100   36 
for multiple exons (at 
least two exons 
concordant : 
sensitivity:100 
specificity: 91 
More than one exon of the RhD 
gene must be examined. 
Conventional PCR might be 
unsuitable for diagnostic use. 
Johnson, L. et  al. Vox 
Sanguinis 85: 222-
223 
Case study 
German
y 
2002 
Retro
specti
ve 
Evaluation of real-time 
PCR method for the 
detection of RHD, C, 
c, E and e 
Prediction of foetal 
RhD and Rh CcEe 
phenotype from 
maternal plasma 
with real-time PCR 
Real-time 
PCR / 
serology 
ff DNA 
from 
thawed 
excess 
plasma 
Exon 7, RHD 
psi - and RHD 
psi 
4 replicates 
16 mostly 
alloimmunised 
pregnant women 
11 - 38 weeks 
pregnant 
1 false negative, at least 
two positive results 
needed for overall 
positive tests result 
D status determined in 26 out of 27 
cases 
Legler, T. et  al. 
Transfus Apheresis 
Sci 27(3): 217-23 
10/25 
France 
2002 
Prosp
ective  
Foetal RhD 
genotyping in 
maternal serum 
during the first 
trimester of 
pregnancy 
New 
quantitative 
real-time 
PCR/ PCR of 
DNA from 
invasive 
procedure or 
serology 
ffDNA from 
serum  2 replicates 
102 RhD- women 
in first trimester 
undergoing genetic 
counselling 
100% detection rate / 
62 positive and 40 
negative fetuses 
identified 
Sera used: Recommend technique 
for routine application 
Costa, J.-M. et  al. Brit 
J. of Haem 119: 255-
260 
11/25 
UK 
2002 
Prosp
ective 
To develop a clinically 
useful foetal RHD 
genotyping assay that 
detects only RHD and 
not RHD psi or RHD-
CE-Ds 
Prediction of foetal D 
status from maternal 
plasma: introduction 
of a new non-
invasive foetal RhD 
genotyping service 
Real-time 
PCR/ PCR of 
DNA from 
invasive 
procedure or 
serology 
ffDNA from 
plasma 
Exons 4, 5 and 
6  
137 RhD- women 
8-42 weeks 
pregnant 
100% detection 
Plasma used: non-invasive 
combination of the sensitivity of 
real-time PCR with an improved 
RhD typing assay to distinguish 
RhD from RhDψ enables highly 
accurate prediction of foetal D 
status. More DNA found when fetus 
was female than in male 
pregnancies. Non-invasive 
technique more accurate in twin 
pregnancy than invasive. 
Finning, K.M. et  al. 
Transfusion, 42:1079-
1085 
14/25 
Switzerl
and 
2001 
Prosp
ective  
Risk free 
simultaneous 
prenatal 
identification of 
foetal Rhesus D 
status and sex by 
multiplex real-time 
PCR using cell free 
foetal DNA in 
maternal plasma 
Novel 
multiplex 
real-time 
PCR / PCR 
of DNA from 
invasive 
procedure 
ffDNA from 
plasma   
34 maternal 
plasma samples 
from rhesus D 
negative pregnant 
women, II trimester 
about to undergo 
invasive procedure 
Correctly: 12/13 Rhesus 
D positive males, 5/5 
Rhesus negative males, 
100% female RhD 
positives or negatives 
First report describing the 
determination of multiple foetal loci 
from cell free foetal DNA. Both loci 
are amplified with the same 
efficacy; Rhesus D could be 
detected in highly diluted samples. 
Suitable for automation. 
Zhong, X.Y. et  al.       
Swiss Med Wkly 131 
(5-6): 70-74 
10.5/25 
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Australi
a 
2001 
Prosp
ective  
Genotyping foetal 
DNA by non-invasive 
means: extraction 
from maternal 
plasma 
Real-time 
PCR / 
serology 
ffDNA from 
plasma   
26 RhD negative 
women pregnant 
with RhD positive 
fetuses 9-34 
weeks pregnant 
100% accuracy, all RhD 
genes could be 
amplified 
Experiment might not have been 
carried out blind. Different times of 
clearance of foetal DNA postnataly 
have been discovered. 
Nelson, M. et  al. Vox 
Sang 80: 112-116 4/25 
UK 
1999 
Prosp
ective 
To develop a non-
invasive method for 
determining foetal 
RhD status in order to 
provide improved care 
for women most at risk 
Non-invasive RNA-
based determination 
of foetal Rhesus D 
type: a prospective 
study based on 96 
pregnancies 
Reverse 
transcription 
PCR / 
serology 
mRNA 
from 
erythroblas
ts 
Intron 4 of 
RhD and CE ( 
control), exon 
10 
 
96 RhD negative 
women: various 
stages of gestation 
about to undergo 
invasive 
procedures 
Overall 75% accuracy 
rates                          III: 
85%; II: 82%; I: 48% 18 
false negatives 
Suggest that reverse transcription 
may be a useful and perhaps more 
sensitive alternative to standard 
genomic PCR 
Cunningham, J. et  al. 
Brit. J. of Obstet 
Gynaecol 106:1023-8 
10.5/25 
USA 
1999 
retros
pectiv
e 
To investigate whether 
foetal RhD status can 
be determined in 
sensitised RhD 
negative pregnant 
women with RhD 
heterozygous 
partners. 
Non-invasive 
determination of 
foetal RhD status 
using foetal DNA in 
maternal serum and 
PCR 
PCR and 
nested PCR / 
serology 
ffDNA from 
serum Exon 7  
Frozen serum of 
20 sensitised RhD- 
women 15-36 
weeks pregnant 
with RhD+ fetus 
in 70% (14) RhD+ 
fetuses were detected, 
no false positives         
PCR: 10/20          
nested PCR: 10/16 
Detection of foetal RhD sequence 
in maternal serum of sensitised 
women 
Bischoff, F.Z. et  al. J 
of Social Gynecol. 
Investig 6: 64-9. 
9.5/25 
UK 
1998 
Prosp
ective    
Assess the feasibility 
of fetal RHD 
genotyping using fetal 
DNA extracted from 
plasma samples 
Prenatal diagnosis of 
foetal RhD status by 
molecular analysis of 
maternal plasma 
Fluorescenc
e based PCR 
/ serology or 
PCR of 
amniotic fluid 
ffDNA from 
plasma Exon 10  
57 RhD- (12-I), 
(30-II), (15-III) 
II and III: 100% 
detection rate            
I: 2 RhD+ fetuses 
undetected (no RhD 
DNA), 10 samples 
correctly genotyped 
Plasma used: genotyping can be 
performed rapidly and reliably 
beginning with the 2nd trimester 
Lo, D.Y.M. et  al. 
NEJM, 339: 1734-8 11/25 
Netherla
nds 
1998 
Prosp
ective 
letter 
 
Detection of foetal 
RhD-specific 
sequences in 
maternal plasma 
PCR of 
serum / PCR 
of amniotic 
cell DNA 
ffDNA from 
plasma Exon 7  
31 RhD- 16-17 
week and 12 RhD- 
not pregnant 
(control) 
All negatives were 
correctly identified / 18 
(=all) RhD+ fetuses 
correctly identified 
Plasma PCR is promising in 
prenatal tests 
Faas, B.H.W.  et  al.     
The Lancet 352:1196 11/25 
Ongoing research/unpublished 
UK   
Further developments of 
non-invasive prenatal 
diagnosis using maternal 
plasma? TCC and a 
source of foetal DNA 
    200+ multi-ethnic women,  
 
 
 
 
 
 
Avent, N. et  al.  
UK   
Identification of foetal 
genotype in uteri using 
DNA extracted from 
maternal plasma. 
    
100 primigravidae 
with unknown Rh 
status 
  Urbaniak, S. et al.  
Paternal RhD genotyping 
Switzerl
and 
2003 
  
Determination of RhD 
zygosity using real-time 
quantitative PCR 
      
Real-time PCR developed for the 
determination of RhD gene and the 
fetal Y chromosome from maternal 
plasma can be used to determine 
the paternal RhD genotype 
Li, Y.et al  Swiss 
Medical Weekly, 
133(31-32): 442-5 
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Annex 3:  Numbers and ratio of RhD-positive and RhD-negative babies reported in 18 studies 
 
 
 
RhD positive RhD negative  Sample size 
 Number % Number % 
Reference List 
Number 
213 137 64.32 76 35.68 87 
31 17 54.84 14 45.16 2 
24 12 50.00 12 50.00 58 
17 12 70.59 5 29.41 59 
283 179 63.25 104 36.75 60 
114 82 71.93 32 28.07 46 
102 62 60.78 40 39.22 63 
20 14 70.00 6 30.00 48 
57 39 68.42 18 31.58 10 
2543 1549 60.91 994 39.09 49 
31 18 58.06 13 41.94 86 
47 36 76.60 11 23.40 45 
45 24 53.33 21 46.67 65 
96 56 58.33 40 41.67 6 
842 649 77.08 193 22.92 44 
58 34 58.62 24 41.38 88 
28 23 82.14 5 17.86 75 
 
2380   1465  61.5  915  38.5 11  
Total 6931 4408 63.60 2523 36.40  
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Annex 4:  Molecular bases of the RHD gene 
 
The RHD and the RHCE gene were cloned in 1990, which allowed thorough investigation and characterisation of the molecular bases 
of these two highly homologous (93.8%) genes.  RHD and RHCE are situated in tail-to-tail configuration on chromosome one.  They 
are arranged in 10 exons each and the RHD gene is flanked by two 9-kb regions of 98.6% identity, the Rh boxes.  The gene products, 
the Rh antigens, are 416 amino acid transmembrane proteins presumably involved in ammonia and ammonium transport.  The Rh 
proteins have 12 hydrophobic transmembrane domains and 6 extracellular loops [13, 14]. 
 
The homology between the two genes challenges RhD genotyping because the RHCE gene is nearly universally present and 
sequences have to be carefully selected for RHD genotyping to be specific.  Two major differences between RHD and RHCE have 
been discovered and subsequently exploited for the development of PCR reactions.  These are a 3' untranslated region of exon 10 of 
RHD, which is not present in RHCE, and a 600-bp difference in intron 4 between RHD and RHCE [50]. 
 
The two proteins differ by 32 to 35 amino acids.  Nine of these RhD specific amino acids are situated at the extracellular surface of the 
red blood cells, defining the numerous epitopes on the six extracellular loops of the RhD protein explaining the high serological 
complexity of the RhD antigen [51].  
 
The absence of one or more D epitopes in RhD positive individuals can lead to qualitative variants, which are able to produce 
antibodies to the missing parts of the antigen when exposed to the whole D antigen.  These D variants are called partial D.  Seven 
different categories of partial D have been established.  DIV lacks the most epitopes and is the most frequent type, with gene 
frequencies of 0.02-0.05% ([52] and references therein).  The DIV phenotype is the only known D variant phenotype that can make anti-
D antibodies that are clinically significant in that they are capable of causing severe HDN and neonatal death.  Serology and 
genotyping are required to type partial D women D-negative since a RhD-positive fetus will be problematic in these pregnancies.  But 
when polyclonal antibodies are used for RhD typing these women will type RHD positive [52]. 
 
There are three genetic mechanisms that result in partial-D and D-variants.  
 
• Substitution of part of the RHD gene with RHCE 
• Deletion of part of the RHD gene 
• Mutations resulting in single amino-acid substitutions in the extracellular parts of the polypeptide 
 
A further group of D variants is the weak D type.  This is characterised by a qualitatively normal D antigen, which is expressed at a low 
level.  These variants are caused by nucleotide changes resulting mostly in point mutations in the transmembrane or cytoplasmic 
region of the polypeptide.  This presumably affects efficient expression or correct insertion into the membrane resulting in a reduced 
number of copies on the red cell surfaces. 
 
Weak D individuals are required to be typed as D-positive as some of them are able to cause alloanti-D immunisation [53].  This is 
important for fetal genotyping as weak D fetuses might cause sensitisation of the maternal circulation.  
 
Very weak forms of D are Del, which can be found in individuals in the Far East, and Rhnull as well as Rhmod. The latter two are caused 
by mutations in the RHAG gene, a homologous gene involved in guiding the RhD and RhCE proteins in the red cell membrane.  
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The RhD negative phenotype occurs in Caucasians with a frequency of ~15% and is most commonly characterised by homozygosity 
for a deletion of RHD.  RhD negativity is less frequent in Africans or Asian.  But the negative phenotype in Blacks is more commonly 
caused by two specific variant genes: 
• RHDΨ an RHD pseudogene which contains a 37bp insertion in exon 4 and a nonsense mutation in exon 6 and 
• RHD-CE-DS, a hybrid gene comprising exons 1, 2, and the 3' end of exon 3 of RHD, the 5' end of exon 3 and exons 4 7 of 
RHCE, exons 9 and 10 of RHD, and exon 8 is undetermined 
 
Individuals with these gene variants possess at least part of the RHD gene but lack the antigen on their erythrocytes.  Testing for these 
genes in a mixed population requires a test that either positively distinguishes RHDΨ from RHD, or gives a D  result when RHD  is 
present.  Overall, 67% of RhD negative black individuals have RHDΨ and 15% RHD-CE-Ds.  In African-Americans, the corresponding 
figures are 24% and 22% ([54] and references within).  
 
See [14, 50, 54, 55] for more detailed reviews on RHD variant genes. 
